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Abstract 
Background 
Reducing severe acute respiratory illness (SARI)-associated mortality in African children 
remains a public health priority and an immense challenge. The pneumococcal 
conjugate vaccine (PCV) was introduced into the South African routine immunization 
programme in 2009. The objectives of this study were: 
I. To describe the demographic characteristics, clinical presentation, respiratory 
pathogens of children aged <5 years hospitalized with SARI in an urban (Chris 
Hani-Baragwanath Hospital, Soweto) and a rural (Matikwana and Mapuleng 
Hospitals, Mpumalanga) setting in South Africa from 2009-2013 and  
II. To compare the factors associated with mortality among children aged <5 years 
hospitalized with SARI in these two sites separately.  
 
Methods 
Hospitalized children with SARI were enrolled into an active, prospective sentinel 
surveillance program. Clinical and epidemiologic data were collected until discharge. 
Nasopharyngeal aspirates were tested for influenza (A and B) and eight other 
respiratory viruses. In-hospital case-fatality proportion (CFP) and risk factors for 
mortality were determined for each hospital site separately using unconditional logistic 
regression.  
 
Results 
The in-hospital CFP was significantly higher in the rural (6.9%, 103/1486) than the 
urban (1.3%, 51/3811) site (p<0.001). This was observed among both HIV-infected 
(urban: 6.6%, 17/257) vs. (rural: 12.9%, 30/233) (p=0.019) and HIV-uninfected children 
(urban: 0.6%, 13/2236) vs. (rural: 4.2% 36/857) (p<0.001). In the urban site the only 
factor that is independently associated with death on multivariate analysis was HIV 
infection (odds ratio (OR) 12.1, 95% confidence interval (CI) 5.8-25.2). In the rural site 
HIV infection (OR 3.5, 95% CI 1.7-6.9), age <1 year (OR 3.5, 95% CI 2.0-6.1) vs. 1-4 
years, any respiratory virus detected (OR 0.4, 95% CI 0.2-0.6), pneumococcal infection 
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(OR 4.5, 95% CI 1.8-10.8) and malnutrition (OR 12.8, 95%CI 1.2-134.6) were 
independently associated with mortality.  
 
Conclusion 
SARI mortality was higher in the rural setting. Even in the era of PCV availability 
pneumococcus is still associated with mortality in rural areas. Efforts to prevent and 
treat HIV infections in children and reduce malnutrition may reduce SARI deaths. 
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Chapter 1 
1.0  Introduction 
This chapter provides an overview of the burden of severe acute respiratory illness 
(SARI) in children globally and also in Africa and its public health significance with a 
particular focus on risk factors for mortality. This chapter also includes the problem 
statement, study justification, aim and objectives of the study and a literature review.  
 
1.1  Background 
Reducing the substantial public health burden of SARI in African children is still a major 
priority and an immense challenge(1). According to WHO’s case definition, SARI is an 
acute respiratory infection with: history of fever or measured fever of ≥ 38 C°; and 
cough; with onset within the last 10 days; and requires hospitalization. (2)  
Pneumonia is defined as an infection of the lungs that is caused by viruses, bacteria, 
fungi, or parasites. It is characterized primarily by inflammation of the alveoli in the lungs 
or by alveoli that are filled with fluid. Therefore SARI is a more inclusive case definition 
than pneumonia because it includes other non-pneumonia causes of PRTI such as 
bronchiolitis. For this surveillance program, a case of SARI was defined as a 
hospitalized person with illness onset within 7 days of hospitalization meeting age-
specific inclusion criteria as follows; Children two days to under 3 months of age with a 
physician’s diagnosis of acute lower respiratory illness (ALRTI) or sepsis, children aged 
3 months to ≤ 5 years with a physician’s diagnosis of ALRTI (which include pneumonia, 
bronchitis, pleural effusion and bronchiolitis). 
Pneumonia is the major cause of death in children < 5 years of age globally, it accounts 
for about 1.4 million deaths annually (1) most of which are recorded in low and middle 
income countries, sub-Saharan Africa is disproportionately affected accounting for more 
than half of pneumonia deaths globally (1). Pneumonia is the commonest respiratory 
infection in children requiring hospitalization (3). 
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In South Africa, pneumonia and influenza was the second leading cause of death in 
children <5 years in 2013, and was responsible for about 10% of deaths in this age 
group. In infants, cardiorespiratory disorders specific to the perinatal period are the 
leading causes of death, accounting for 14% of deaths in this age group, influenza and 
pneumonia causes 9% of deaths in infants. (4) 
Reducing mortality in children less than 5 years of age was one of the Millennium 
Development Goals (MDGs) which is now covered under the umbrella of good health 
and wellbeing in the sustainable development goals (SDGs). However, to reduce the 
burden of SARI remains a major challenge in Africa. (1) Possible approaches include 
improved access to vaccines for common causes of pneumonia, reduction in HIV, 
mother to child transmission (MTCT), Integrated management of childhood illness 
(IMCI) and indoor air pollution.(5) Preliminary studies have suggested that SARI 
mortality is lower in urban than in rural settings in South Africa (6).  
 
1.2  Problem statement 
Despite improvement in patient survival and the advances in the development of new 
antimicrobials and vaccines, pneumonia continues to carry a high morbidity and 
mortality rate in children especially those living with HIV. Several studies have been 
carried out in South Africa looking at mortality from SARI in children <5 years, but none 
have examined specifically the differences in risk factors for SARI-related mortality in 
urban and rural areas in South Africa. There have been studies describing children born 
in rural areas to be at greater risk of death of any cause before 5 years of age possible 
reason being access to care (7, 8). 
 
1.3 Justification 
This study will describe individuals at increased risk of mortality and identify risk factors 
for in- hospital mortality in children < 5 years of age with SARI that could be targeted for 
public health intervention in rural and urban settings. Studies have shown that children 
born in rural areas are at greater risk of death of any cause before 5 years of age 
possible reason being access to care (7, 8). It would be interesting to describe this in 
our setting and in particular to see if there is a mortality differential in patients with SARI 
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between rural and urban areas. If mortality is elevated in rural areas, specific 
interventions could potentially be targeted to address risk factors for death in these 
areas. Describing the risk factors for SARI-related deaths in both rural and urban 
settings could potentially bring about improved access to interventions to reduce 
pneumonia deaths in South Africa.  
 
 
1.4 Literature Review 
Pneumonia remains the major cause of death worldwide in children under 5 years of 
age (9). Pneumonia is an inflammatory lung disease affecting primarily the microscopic 
air sacs also known as the alveoli.(10) Children, older adults and people with chronic 
diseases like asthma, chronic obstructive pulmonary disease, heart failure, sickle cell 
anaemia and HIV are at elevated risk for pneumonia. (11) Inhaled infectious organism 
must bypass the host's immune and non-immune defensive mechanisms in order to 
cause pneumonia. (12) The symptoms and signs of pneumonia are mostly nonspecific, 
they can range from mild to life threatening and vary based on the infectious organisms 
involved, age of the patient and the general health status of the patient.(13) Typical 
symptoms and signs include a cough, fever, chest pain and difficulty in breathing. 
Pneumonia may develop in the lung or it can be from a focal complication of a systemic 
inflammatory process.(14) Understanding the cause of pneumonia is important because 
pneumonia treatment depends on its cause. Bacterial pneumonia is treated with 
antibiotics while viral pneumonia can be treated symptomatically and with antivirals -
oseltamivir for influenza. Furthermore there is a growing need to identify respiratory 
pathogens that contribute to disease development because vaccines targeting specific 
organisms are now available to prevent infections with major pathogens such as 
Streptococcus pneumoniae, Haemophilus influenzae type b (Hib) and influenza virus. 
 
1.4.1 Pathogens associated with pneumonia 
Pneumonia is caused mainly by viruses or bacteria and less frequently by parasites, 
fungi and various chemical agents. Over 100 types of infectious agents causing 
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pneumonia have been identified in patients, very few can be attributed to most of the 
cases, co-infection with both bacteria and viruses may occur in up to 45% of infections 
in children(15). Bacterial pathogens such as Hib, S. pneumoniae and Staphylococcus 
aureus remain important causes of pneumonia in African children. S. pneumoniae is the 
most important bacterial pathogen in African children, it is estimated that about 16% of 
cases of severe pneumonia are caused by pneumococci,(16) hence the introduction of 
pneumococcal conjugate vaccine (PCV) in the South African Expanded Program on 
Immunization (EPI) in 2009. Incidence of pneumococcus and Hib invasive disease has 
decreased markedly in South Africa due to the use of PCV and Hib conjugate vaccine in 
the EPI.(17, 18) Some other bacterial pathogens such as Salmonella spp and 
Escherichia coli may cause pneumonia in children, particularly in HIV-infected children. 
In a recent study conducted in South Africa, the overall prevalence of respiratory viruses 
identified in children under 5 years of age hospitalized with SARI was 78% [rhinovirus 
(37%), adenovirus (26%) ,respiratory syncytial virus (RSV) accounting for 26% and 
enterovirus (10%)]. (6) This is similar to findings in a study conducted in children under 
5 years with SARI in a densely populated urban slum in Kenya reporting 71% overall 
prevalence of respiratory viruses [rhinovirus/enterovirus (47.5%), adenovirus (29.5%) 
and RSV accounting for 20.7%]. (19) Kwofie et al while looking at respiratory viruses in 
children hospitalized for ALRTI in Ghana reported viruses identified as RSV (14.1%) 
followed by Adenoviruses (10.2%), Parainfluenza viruses type 1, 2, 3 (3.1%) and 
influenza B virus (0.8%). (20) In Cambodia, a study on clinical and epidemiological 
characteristics of acute viral lower respiratory tract infection in children reported 55% of 
children with documented viral infection [rhinovirus (34%), RSV (34%), parainfluenza 
virus (8%), human metapneumovirus (8%), influenza virus (6%), bocavirus (3%), 
adenovirus (3%), coronavirus (2%) and enterovirus (1%). (21) 
In a nested case control study, Zar et al reported that RSV was the most frequently 
detected pathogen associated with pneumonia occurring in 23% of cases and 4% of 
controls with OR(95% CI) of 8·05 (4·21–15·38); influenza virus and B pertussis were 
also strongly associated with pneumonia.(22) This was similar to a prospective case-
control study carried out by Benet et al on etiology and factors associated with 
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pneumonia in children under 5 years of age in Mali which reported S. pneumoniae, 
human metapneumovirus, RSV and influenza A virus as independent organisms 
associated with pneumonia.(23) In a similar study with healthy controls, Pretorius et al 
reported that Influenza virus with (attributable fraction (AF): 86.3%; 95%CI: 77.7–
91.6%), RSV (AF: 83.7%; 95%CI: 77.5–88.2%) and human metapneumovirus (AF: 
85.6%; 95%CI: 72.0–92.6%) infections were associated with severe disease, while 
adenovirus (AF: 36.4%; 95%CI: 20.6–49.0%) and rhinovirus (AF: 46.9%; 95%CI: 37.6–
56.5%) were only moderately associated.(24) 
However, most of these studies didn’t test for bacteria. Diagnosis of bacterial 
pneumonia is complex as finding pneumococcus in the nasopharynx may represent 
colonization (25) hence the need to distinguish between S. pneumoniae that is simply 
colonizing the upper respiratory tract and S. pneumoniae that is causing pneumonia. 
Blood culture is highly specific for disease but a high percent of pneumococcal 
pneumonia will not be bacteraemic and thus blood culture is insensitive,(26) hence the 
need for better identification of S. pneumoniae independent of culture methods. The 
real-time polymerase chain reaction (PCR) targeting lytA gene on blood samples for 
detection of S. pneumoniae has been found to be highly sensitive and specific,(27, 28) 
and studies suggest it likely represents disease and not colonization but there is still 
some controversy.(27) 
  
1.4.2 Risk factors for pneumonia 
Risk factors that predispose to pneumonia in children aged under 5 are low birth weight, 
HIV co-infection, low socioeconomic status, being unimmunized, overcrowding, 
malnutrition, lack of exclusive breastfeeding in the first four months of life, parental 
smoking, indoor air pollution, zinc deficiency, vitamin A deficiency, co-morbidity like 
diarrhea, heart disease, asthma, maternal education, mother’s experience as a 
caregiver and passive care–seeking behavior. (29) Nair et al in a study on global and 
regional burden of hospital admissions for severe acute lower respiratory infections in 
young children in 2010: a systematic analysis reported that disease incidence was 
highest in neonates aged 0-27 days (68·6 episodes per 1000 per year, 95% CI 47·8–
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98·4) and infants aged 0–11 months (51·8 episodes per 1000 per year, 44·8 –59·8). (3) 
The HIV epidemic has had a major impact on the burden and epidemiology of  
pneumonia in children, the increasing number of pneumonia admissions in HIV infected 
patients has contributed to the general increase in hospitalization and deaths due to 
pneumonia in South Africa. (30) There are a few studies on SARI comparing the 
epidemiology in rural and urban areas. Studies have shown that children born in rural 
areas are at greater risk of death of any cause before 5 years of age. (7, 8)  
 
 
1.4.3 Risk factors for mortality 
Pneumonia is the commonest cause of hospitalization and death, especially in Sub-
Saharan Africa where there is high concentration of children living with HIV. HIV-
infected children have a higher risk of developing pneumonia and of more severe 
disease than children without HIV (6, 30).  
In a systemic review and meta-analysis of observational studies from 1974 to January 
2014 reporting on risk factors for death from acute lower respiratory illness (ALRI) in 
children below five years in low- and middle income countries, the risk factors showing 
strong association with mortality among children with pneumonia  were HIV/AIDS, 
diagnosis of very severe pneumonia according to WHO definition, children less than 2 
months of age, low birth weight, co-morbidity with chronic diseases, severe malnutrition, 
Pneumocystis carinii (Pneumocystis jirovecii) diagnosis, prematurity and inadequate 
breastfeeding practices. (31) 
In a case series study from 8 countries on SARI deaths in sub-Saharan Africa and the 
role of influenza, 67.9% of influenza virus–positive deaths were HIV infected (32).  
Furthermore, a study by Cohen et al looking at viral-associated ALRTI among children < 
5 years of age in a high HIV prevalence setting in South Africa revealed that incidence 
of lower respiratory tract infection (LRTI) was 1.1 to 3.0-fold greater in HIV-infected 
children than HIV-uninfected children with a higher case fatality ratio (OR: 4.2, 95% CI: 
2.6–6.8) and HIV-infection was a risk factor for death on multivariate analysis (OR: 3.7, 
95% CI: 2.2–6.1) (6). This suggests that despite the availability and wide coverage of 
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antiretroviral therapy, HIV infection still remains a major risk factor for SARI mortality in 
children in sub-Saharan Africa. However, changes in prevention of mother-to-child 
transmission (PMTCT) and pediatric highly active antiretroviral therapy (HAART) from 
2004 to 2014 in South Africa have been remarkable with the increase in HIV-PCR 
testing in infants less than two months old and the decreasing trend in the percentage of 
those testing positive. Moreover early MTCT has greatly reduced from over 20% in 
2014 to less than 2% in 2015. (33-35) However, studies have shown that HIV-exposed 
uninfected (HIV-EU) children have a higher infectious morbidity and mortality especially 
in the first 2 years of life compared to the children of HIV-negative mothers (HIV-
unexposed). (36-38) In a study carried out in Soweto South Africa, it was shown that 
HIV-EU infants aged <6 months experienced elevated incidence of LRTI hospitalization 
when compared with HIV unexposed uninfected (HIV-UU) infants. In addition, once 
hospitalized, HIV-EU infants were more likely to have a prolonged hospitalization and to 
die in-hospital compared with HIV-UU infants, highlighting the need for this group to be 
considered an at-risk group for severe pneumonia.(39) This poor health outcome may 
be due to infant feeding practices as infected-mothers may be less able to breastfeed or 
may choose replacement feeding to reduce the risk of HIV-transmission. (40) Other 
potential contributing factors include early maternal death, increased exposure to 
infections, and immune abnormalities resulting from in utero exposure to HIV and 
antiretroviral medications.(40)   
 
Looking at age, 11·3 million children younger than 5 years were admitted to hospital for 
severe ALRI in developing countries, with an estimated case fatality ratio of 2·3% (95% 
CI 1·6–3·4). (41) Sonego et al in a systemic review and meta-analysis of observational 
studies in 2015 also reported that neonates and infants were at higher risk of mortality 
due to SARI compared to older children < 5 years odds ratio (OR) of 5.22 (1.70-16.03) 
for children below two months of age. (31) 
 
Malnutrition and pneumonia are two of the biggest causes of death in children, in a 
systemic review looking at pneumonia in severely malnourished children in developing 
countries, Chisti et al reported that children with moderate or severe malnutrition with 
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pneumonia were at higher risk of death, (42) and in a score for risk of mortality among 
infants with pneumonia, very low weight for age and refusal to feed contributed as much 
to risk of mortality as hypoxia, (43) moreover Rice et al in the bulletin of the WHO 
reported that the most consistent and strongest relationship between malnutrition and 
increased risk of death was observed for children with acute respiratory infection and 
diarrhea. (44) 
In a case–control study conducted in four healthcare centers close to Utrecht in the 
Netherlands, a strong male predominance of  ALRTI in children < 5 years old was 
reported (11.2 out of 1,000 among males and 5.7 out of 1,000 among females), (45) 
Nair et al also reported higher incidence in boys than girls in a systematic review. (3)  
However despite having more males with ALRTI, several studies have shown that the 
female sex is associated with increased odds for mortality, (3, 46) which is also 
supported by Sonego et al in a meta-analysis of 23 studies on 20385 children that 
female sex was associated with a 15% increase in the odds for mortality, (31) possible 
reasons being inequality related to sex in the quality of health care provided, health 
seeking behavior in the community and also biological differences. A study conducted in 
India looking at the risk factors for death in children aged 1-59 months admitted with 
community acquired pneumonia however showed that the difference in mortality due to 
pneumonia among male and female children was not statistically significant (P=0.12). 
(47)   
 
1.4.3.1 Respiratory pathogens as a risk factor for mortality 
In a case series study from 8 Countries on SARI deaths in Sub-Saharan Africa and the 
role of influenza surveillance from 2009–2012, McMorrow et al reported that rhinovirus 
(14.2%), RSV (13.4%), adenovirus (13%), parainfluenza virus 3 (5.3%) were observed 
amongst those that died from SARI in children < 5 years old.(32) 
In HIV-infected persons the incidence of influenza-associated ALRTI was 4-8 times 
greater than the incidence in HIV-uninfected persons and those with HIV are more likely 
to die (OR 3.9, 95% CI 1.1–14.1) (48), this is in keeping with a study conducted by 
Schnell et al looking at risk factors for pneumonia in immunocompromised patients with 
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influenza which reported that immunocompromised patients with influenza are at higher 
risk of death from pneumonia (49). Several studies have described a high burden of 
RSV-associated pneumonia with HIV-infected children having a higher risk of 
hospitalization with RSV-associated ALRTI and a poorer outcome than HIV-uninfected 
children (50, 51) 
Bacterial pneumonia is associated with higher mortality than viral pneumonia. In 2009, 
in a study on global burden of disease caused by S. pneumoniae in children younger 
than 5 years, O’Brien et al reported approximately 826,000 deaths in children < 5 years 
of which about 91,000 occurred in HIV-positive and approximately 735,000 in HIV-
negative children.(52) Rudan et al in 2010 in a systematic review  looking at etiology 
and epidemiology of childhood pneumonia for 192 countries reported that 33% of 
pneumonia death were caused by S. pneumoniae with Haemophilus influenzae 
accounting for 16% of death (53). In India, Farooqui et al in 2010 estimated about 
560,000 severe episodes of pneumococcal pneumonia with about 105,000 
pneumococcal deaths.(54) In South Africa, pneumococcal co-infection was identified by 
Cohen et al as a risk factor for mortality among patients with influenza associated 
severe acute respiratory illness (OR 4.1, 95% CI 1.5–11.2). (55) PCP is an important 
pathogen independent of patient’s HIV status. It has been reported in both HIV–infected 
and HIV-uninfected children (especially those that are immunocompromised).(56) In 
2000, Zar et al reported that 9.9% of HIV-infected had PCP.(57) Furthermore, in 2014 
Morrow et al in a study on pneumocystis pneumonia in South African children 
diagnosed by molecular methods reported that children with PCP had a higher case 
fatality proportion (CFP) (32.1%) compared to those without PCP (17.2%), relative risk 
(RR) 1.87: 95% confidence interval (CI) 1.11-3.15. (58) 
 
 
1.4.4 Vaccines for prevention of pneumonia 
S. pneumoniae has been identified as the leading bacterial cause of pneumonia in 
children, it is also recognized as a common cause of super-imposed bacterial infection 
in children with respiratory virus-associated pneumonia (59, 60). According to Madhi et 
al in 2004, in a double-blinded, randomized, placebo-controlled clinical trial in 37,107 
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infants that were fully immunized in Soweto, South Africa, it was reported that the 9-
valent pneumococcal conjugate vaccine prevented 31% (95% CI: 15−43%) of viral 
pneumonias in hospitalized children. (60) However, vaccines are now available to 
prevent infections with pathogens like S. pneumoniae, Hib and influenza virus, while 
RSV vaccine is being actively pursued (61, 62).  
In South Africa, Hib was introduced into the EPI in 2000, PCV-7 in April 2009 and with 
the 13-valent PCV (PCV-13) replacing PCV-7 in May 2011. (63) Influenza vaccine is 
available in South Africa but coverage is exceptionally low, (64) ±1 million doses of 
influenza vaccines are distributed each year but there are ±20 million individuals in the 
risk groups targeted (65) In South Africa in 2009, pertussis vaccine changed from whole 
cell to acellular pertussis vaccine in the EPI. (66) 
In a multi-center study carried out in South Africa it was reported that PCV vaccination 
was associated with a 69% (95% CI 7-90) reduced odds of hospitalization for vaccine–
serotype invasive pneumococcal disease (IPD).(67) In 2014, von Gottberg et al also 
reported that IPD rates among South African children reduced remarkably by 2012. (68)  
A case-control study was conducted by Madhi et al in 2014 to establish the 
effectiveness of PCV vaccine looking at the endpoint of clinical pneumonia in South 
Africa.(63) These studies are helpful in quantifying the direct effectiveness in routine 
use of these vaccines, however the public health impact of these vaccines is yet to be 
fully quantified. 
 
1.4.5 In-Hospital death  
Nair et al in the systemic review of global and regional burden of hospital admission for 
severe ALRTI in young children reported that about 62% of children with severe ALRI 
were admitted into the hospital and amongst these admissions about 19% died in 
hospital. Nearly 99% of deaths outside the hospital take place in developing countries 
(3, 32).  
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1.5 Research Question  
What are the demographic, clinical and pathogen specific factors associated with in-
hospital mortality among children aged < 5 years of age with SARI in urban and rural 
settings in South Africa? 
 
1.6 Aim 
This study aims to compare the in-hospital mortality and factors associated with 
mortality among children < 5 years hospitalized with SARI in a rural and an urban area 
in South Africa from 2009 to 2013.  
 
1.6.1 Specific Objectives 
The specific objectives of this study are: 
  
1. To describe the demographic characteristics, clinical presentation and respiratory 
pathogens of children < 5 years of age hospitalized with SARI in hospital sites in 
an urban and a rural area of South Africa. 
2. To identify the risk factors for mortality among children < 5 years of age 
hospitalized with SARI in an urban and a rural area of South Africa separately. 
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                                                        CHAPTER 2 
2.0 MATERIALS AND METHODS 
The study design, study population and setting, selection of study site, data sources, 
case definition and study procedure are reviewed in detail in this chapter. The exposure 
and outcome variables are defined; data management, statistical methods, data 
analysis and ethical considerations are also discussed. 
 
2.1  Study design 
This study is a cross sectional study through secondary analysis of data derived from 
SARI surveillance conducted by the National Institute for Communicable Diseases 
(NICD). The SARI surveillance data could potentially be described as a cohort data 
because patients are enrolled at presentation to hospital due to their exposure to SARI 
and followed for the period of their hospital stay to record the outcome; hence it is a 
prospectively collected cohort data. But for this study, data on both exposure and 
outcome are collected at the same point in time, and the period from admission to 
outcome was very short hence the assessment was a cross-sectional study design. 
Data collected from February 2009 to December 2013 will be used for this study. 
 
 
2.2  Study Setting 
The data came from prospective, active, hospital-based sentinel surveillance for SARI 
which was implemented in February 2009 in three provinces of South Africa. Urban 
hospital data from Chris Hani-Baragwanath Academic Hospital (CHBAH) of Gauteng 
Province, and rural hospital data from Matikwana and Mapulaneng Hospitals of 
Mpumalanga Province in South Africa was used for this study. The two peri-urban sites 
were excluded from this study in order to allow comparison between the rural and urban 
settings.  
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The Chris Hani Baragwanath Hospital was established in 1941 and it is the 3rd largest 
hospital in the world and the largest hospital in the southern hemisphere in terms of 
hospital beds with approximately 3'200 beds and about 6'760 staff members. (69) 
Located in the Soweto area of Johannesburg, it is a tertiary level academic hospital 
serving a population of ±1.3 million people. It is a highly specialized hospital with about 
70% of all admissions being emergencies.(69) 
The Mapulaneng (Bushbuckridge) and Matikwana (Mkhuhlu) hospitals are in a rural 
area of Mpumalanga province, South Africa. Matikwana hospital is located adjacent to 
the Agincourt demographic surveillance site; therefore population surveys on 
demographic data are captured annually. Mapulaneng have high care facilities with 3 
ICU beds. Matikwana have no ICU. These hospitals service a population of ±450,000 
people. 
These sites were selected for the SARI surveillance based on their geographical 
location; urban and rural sites with different climatic zones, capacity at the sites for 
specimen storage and transport, interested and committed clinicians and where routine 
evaluation of SARI cases can be accompanied by some investigations such as blood 
culture and HIV serology testing which enhances case evaluation. 
 
2.3  Surveillance program - Primary data source  
Surveillance for SARI was established in February 2009 because there was a global 
concern that an influenza pandemic could occur which led to the establishment of 
sentinel hospital-based surveillance of severe acute respiratory infections (SARI) in 
some countries.(70) The April 2009 H1N1 pandemic further supported the need to 
routinely monitor severe influenza. The South African SARI surveillance was already in 
place before this pandemic. Hospital-based, active, prospective sentinel surveillance 
[SARI program] was implemented in 3 of the 9 provinces of South Africa in 2009. 
Matikwana and Mapulaneng hospitals in rural area of Mpumalanga and Chris Hani-
Baragwanath Academic Hospital (CHBAH) in an urban area of Gauteng Province in 
February and Edendale Hospital in a peri-urban area of KwaZulu-Natal Province in 
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September 2009. A surveillance site was introduced in June 2010 at 
Klerksdorp/Tshepong hospital complex located in a peri-urban area of the Northwest 
Province. For the study described in this report, only data from the CHBAH and 
Matikwana and Mapulaneng hospitals were included. The other sites will not be 
discussed further. 
The aim of the primary study was to determine trends in number of SARI cases at 
sentinel surveillance sites and determine the relative association of influenza and other 
respiratory viruses such as adenovirus, human metapneumovirus, RSV, rhinovirus, 
enterovirus and parainfluenza virus 1, 2 and 3 to this disease presentation in a setting 
with a high HIV prevalence.  
 
 
2.4 Case definition  
A case of SARI was defined as a hospitalized person with illness onset within 7 days of 
hospitalization meeting age-specific inclusion criteria as follows; Children two days to 
under 3 months of age with a physician’s diagnosis of ALRTI or sepsis, children aged 3 
months to ≤ 5 years with a physician’s diagnosis of ALRTI (which include pneumonia, 
bronchitis, pleural effusion and bronchiolitis). 
 
2.5 Inclusion criteria for this study: 
Children < 5 years of age hospitalized in either the rural or urban hospital site meeting 
the SARI case definition. 
 
2.6 Study procedures 
All individuals hospitalized from Monday through Friday were eligible for enrollment in 
the surveillance. Weekend admissions were excluded because surveillance officers 
were not screening during weekends. In 2013, enrolment was down-scaled at CHBAH, 
pediatric patients were subsequently enrolled on 2 working days per week. In 2012 
routine collection of information on the children’s weight was commenced in both study 
sites. Total number of children hospitalized meeting study case definition were 
documented throughout the period. Informed consent was obtained from parents or 
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legal guardian to the children before enrollment. History taking on demographic, 
socioeconomic factors, clinical presentation and outcome were documented by means 
of hospital record review and structured interviews. Case report forms were completed 
by study staff, information on patient management was collected and patients were 
followed for in-hospital outcome. Whole blood specimen and nasopharyngeal aspirates 
(NPA) were collected from consenting patients. 
Patient management decisions, admission into the hospital and the intensive care unit 
(ICU), collection of specimens for culture were performed according to attending 
physician’s discretion. In the event that data on patient HIV status was not available 
through record review of results of routine HIV testing by attending physician as part of 
patient management, anonymised linked HIV ELISA or PCR testing was performed 
using a dried blood spot or whole blood specimen if patient consented to this. HIV data 
was anonymised and linked; it is anonymous to the people who receive and hold the 
information such as a research team but contains information or codes that would allow 
others such as physicians responsible for the individual's care to identify an individual 
from it.(69) Monitoring of patients that were enrolled into SARI surveillance was carried 
out until discharge or death to determine in-hospital outcome. 
 
2.6.1 Laboratory Methods 
NPA in viral transport medium and blood specimens were transported to the NICD of 
the National Health Laboratory Services (NHLS) within 72 hours of collection at 4–8°C. 
Multiplex real-time reverse-transcription PCR (RT-PCR) assay was used to test the 
respiratory specimens for 10 respiratory viruses (influenza A and B viruses, adenovirus, 
parainfluenza virus 1, 2 and 3, enterovirus, RSV, human metapneumovirus and 
rhinovirus).(71) RT-PCR has been shown to be significantly more sensitive than 
Fluorescent-Antibody Assays (FA) for the detection of respiratory viruses in clinical 
specimens from children. (71, 72) 
Blood was tested for S. pneumoniae using a single-target (lytA) quantitative RT-PCR 
assay and culture was also carried out by clinicians where indicated according to 
standard practice in the hospital. HIV was tested through anonymised linked dried blood 
spot specimen testing using HIV PCR assay for children aged <18 months and ELISA 
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for individuals aged ≥18months. CD4+ T-cell counts were determined by flow cytometry. 
(73) Tuberculosis was initially tested for using sputum smear microscopy and culture. In 
addition, in 2011 GeneXpert was introduced for the diagnosis of pulmonary tuberculosis 
at some of the sites. (74) Tuberculosis testing was carried out by clinicians where 
indicated according to standard practice in the hospital. 
 
2.7  Study Population and Study sampling 
All patients (children and adults) meeting the SARI case definitions were enrolled into 
the SARI surveillance. For this analysis, the study population comprised all children less 
than 5 years of age hospitalized and enrolled into the SARI surveillance program in 
hospitals from the rural and urban sentinel sites in South Africa from February 2009 to 
December 2013. Children aged 5 years and above and adults were excluded from this 
secondary analysis. Children that were admitted as sleepovers (children in the short 
stay ward that spent less than 48 hours in the hospital) were not included in the analysis 
dataset for CHBAH because the rural site did not have a comparable sleepover ward.  
 
2.8  Explanatory and outcome variables 
The following variables studied for each objective are described below. 
Objective 1: The characteristics were described for patients enrolled at the rural and 
urban sites separately. 
Demographic: Age, sex, race, year, 2 or more doses of pneumococcal vaccine, type of 
housing, number of rooms used for sleeping, number of people sleeping in a room. 
Clinical presentation and in-hospital management: Duration of symptoms, antibiotics 
prescribed on admission, difficulty in breathing, unable to feed and drink, use of oxygen, 
admission into ICU, mechanical ventilation, duration of hospitalization, tuberculosis 
therapy started on admission and in-hospital death. 
Underlying Medical conditions: HIV, tuberculosis, prematurity, reported malnutrition, 
malnutrition (weight for age), chronic lung diseases, asthma, renal disease, heart 
diseases, diabetes and neurological diseases. 
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Respiratory pathogens: Influenza, adenovirus, enterovirus, rhinovirus, RSV, human 
metapneumovirus, parainfluenza virus 1, parainfluenza virus  2, parainfluenza virus 3, 
parainfluenza virus 1, 2 or 3, any respiratory virus, more than 1 respiratory virus, 
pneumococcal infection on lytA PCR, blood culture, relevant bacterial infection on blood 
culture, co-infection with pneumococcus and influenza. 
 
 
Objective 2: 
A separate analysis was conducted to evaluate factors associated with mortality in rural 
and urban settings. 
Outcome Variable: In-hospital death vs. no in-hospital death 
Explanatory Variables: 
Demographic: Age, sex, race, year, 2 or more doses of pneumococcal vaccine, type of 
housing, number of rooms used for sleeping, number of people sleeping in a room. 
Clinical presentation and in-hospital management: Duration of symptoms, antibiotics 
prescribed on admission, difficulty in breathing, unable to feed and drink, use of oxygen, 
admission into ICU, mechanical ventilation, duration of hospitalization, tuberculosis 
therapy started on admission. 
. 
Underlying Medical conditions: HIV, tuberculosis, prematurity, malnutrition (reported), 
malnutrition (weight for age), chronic lung diseases, asthma, renal disease, heart 
diseases, diabetes and neurological diseases. 
Respiratory pathogens: Influenza, adenovirus, enterovirus, rhinovirus, RSV, human 
metapneumovirus, parainfluenza virus 1, parainfluenza virus  2, parainfluenza virus 3, 
parainfluenza virus 1, 2 or 3, any respiratory virus, more than 1 respiratory virus, 
pneumococcal infection on lytA PCR, blood culture, relevant bacterial infection on blood 
culture, co-infection with pneumococcus and influenza. 
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2.9  Data management 
2.9.1 Data Processing  
Surveillance data of patients with SARI from the rural and urban hospitals was obtained 
from the NICD. Demographic information, clinical evaluation and laboratory results of 
each patient were captured into Microsoft access database by laboratory and data 
clerks at the NICD. Data was extracted into Microsoft Excel and imported into Stata 14 
for analysis. Those not meeting the eligibility criteria were excluded (see flow chart 
Figure.1), for each variable missing data were checked.  
Prior to data analysis, all variables were defined. 
 The outcome of interest was in-hospital death. In-hospital death was generated 
from the variable final outcome which could be death, discharge, query, referred 
to step down facility, transferred or unresolved. In-hospital death was defined as 
a categorical variable with 2 levels; ―Yes‖ if the patient died during admission and 
―No‖ for those that were discharged. Those with final outcome recorded as query, 
referred to step down facility, transferred or unresolved were categorized as 
survived (No) as they did not die in the hospital. All individuals with missing 
outcomes were excluded from the logistic regression analysis. 
 All continuous variables were recoded into categories  
 Variable age was generated from the date of birth and date of presentation at the 
hospital. Age was categorized into 2 groups which are <1 year and 1-4 years. 
 Number of rooms used for sleeping in the patients’ house was categorized into < 
2 rooms and ≥ 2 rooms. This variable was included to reflect crowding and 
possibility of exposure to respiratory viruses. 
 The number of people sleeping in a room was also categorized into ≤ 2 people in 
a room or > 2 people in a room. This variable was included to reflect crowding 
and possibility of exposure to respiratory viruses. 
 Duration of symptoms was generated from date of presentation and date of onset 
of symptoms and categorized into < 2 days and ≥ 2 days prior to admission. It is 
the number of days from onset to admission to hospital.  
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 Duration of hospitalization: This variable was generated from the date of 
presentation and date of final outcome. It was then categorized into < 2 days, 2-7 
days and > 7 days. 
 
Some categorical variables were redefined while others were utilized as it was defined 
in the database.   
 Sex was defined as either male or female. 
 Race was defined as blacks and others, others being white, colored or asian. 
 Year was based on the year that the data was collected which was 2009, 2010, 
2011, 2012 and 2013. 
 Type of housing was categorized as brick, iron sheeting, mud and others.  
 2 or more doses of pneumococcal vaccine was labeled as ―Yes‖ or ―No‖ based 
on the number of doses of pneumococcal vaccine received. Yes ―2 or more 
doses‖ while No ―<2 doses‖. One dose is not effective while 2 doses are highly 
effective.(67) 
 HIV status was defined as positive or negative documented from medical records 
of tests done during current or prior admission documented by a clinician. 
 The variable tuberculosis was generated from AFB result, tuberculosis PCR site 
result or tuberculosis culture site result. A positive result from any test was 
considered positive. 
 Parainfluenza virus 1, 2 or 3 was generated from results of each of the 
parainfluenza viruses.  
 More than 1 respiratory virus was generated from the result of the entire 
respiratory viruses. 
 Pneumococcal infection on lytA PCR was defined as the presence of S. 
pneumonia in the blood sample of the patient. 
 Co-infection with pneumococcus and influenza was generated from the results of 
pneumococcal infection and influenza. 
 Invasive bacterial infection on blood culture and relevant invasive bacterial 
infection on culture were recoded from the blood culture result. 
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The relevant invasive bacterial infections were S. pneumoniae, Haemophilus influenzae, 
Klebsiella pneumoniae, S. aureus, Neisseria meningitidis, E. coli, Streptococcus 
agalactiae or group b streptococcus, Pseudomonas aerugenosa and 
Salmonella species. 
 All other variables were defined as the presence ―Yes‖ or absence ―No‖ of the 
attribute. 
Consistency checks were carried out to further affirm the validity and integrity of the 
data; some of the consistency checks done include: 
 Date of admission must be after date of birth 
 Date of admission must be before date of final outcome.  
 Ensure that duration of symptoms meet case definition 
 Ensure that there were results for samples collected. 
Variables with missing data were explored and described.  
 
2.10 Statistical Analysis plan 
The analysis of the data involved three stages which were descriptive analysis, 
univariate analysis and multivariate analysis using binary logistic regression. All 
available data were used for each analysis. 
 
2.10.1 Data Analysis 
Objective 1: Descriptive statistics such as frequencies and percentages was reported 
by means of tables for categorical variables in each hospital site based on the 
demographic characteristics, clinical presentation, underlying medical conditions and 
respiratory pathogens. This was done using the Pearson’s Chi Square test. The 
expected cell number was checked to determine if the Fisher’s exact test was more 
appropriate. The P-value was reported with the descriptive analysis in order to 
determine if the differences in the above listed characteristics between the urban and 
rural hospital sites were significant. 
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Objective 2: Risk factors associated with mortality in each hospital site were 
determined using univariate and multivariate logistic regression analyses. This analysis 
was carried out separately for each hospital site. 
On univariate analysis, binary logistic regression was used to determine factors 
associated with in-hospital mortality. In-hospital death was coded ―1‖ while no in-
hospital death was coded ―0‖. Crude odds ratio (OR) was reported (with 95% 
confidence Interval (CI) and p-values). For each univariate analysis, we used all 
available case information. In the multivariate model, patients with missing data for 
included variables were dropped from the model. All variables that were significant at 
p<0.1 in univariate analysis were evaluated in the multivariate analysis and non-
significant factors were dropped with stepwise backward regression. A two-sided p-
value of <0.05 was considered significant throughout. A goodness of fit test was carried 
out on the final model to determine how well the model fits into the set of variables.  
A similar analysis was carried out restricted to children that died to assess the 
characteristics they presented with. Descriptive statistics such as frequencies and 
percentages were reported for children who died in each hospital site based on the 
demographic characteristics, clinical presentation, underlying medical conditions and 
respiratory pathogens using the Pearson’s Chi Square test or the Fisher’s exact. 
Univariate and multivariate logistic regression analysis were carried out using the 
hospital site as the outcome variable in order to determine factors associated with each 
hospital site. The rural hospital site was coded ―1‖ while the urban was coded ―0‖. Crude 
odds ratio (OR) was reported (with 95% confidence Interval (CI) and p-values). All 
variables that were significant at p<0.1 on univariate analysis were evaluated in the 
multivariate analysis and non-significant factors were dropped with stepwise backward 
regression. A two-sided p-value of <0.05 was considered significant throughout. A 
goodness of fit test was carried out on the final model to determine how the variables fit 
into the model. 
Survival estimates were compared amongst those who died looking at duration of 
symptoms to hospitalization (onset of symptoms to date of hospitalization), duration of 
symptoms to death (onset of symptoms to date of death) and duration of hospitalization 
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to time of death (date of hospitalization to date of death) in the rural and urban sites 
using the Kaplan-Meier survival estimates with a log-rank test for equality of survival 
function amongst children that died.  
Analysis was performed using Stata version14 (StataCorp Limited, Texas, United States 
of America). 
2.11 Ethical consideration 
The study was approved by the University of the Witwatersrand Human Research 
Ethics Committee (Medical) in December 2015. Ethics approval certificate is attached 
(Appendix 2). Permission to use the NICD data was granted (Appendix 3). The protocol 
for the original study was approved by Ethics committee of University of the 
Witwatersrand. Annual recertification was obtained from the Ethics committee 
(Appendix 4). 
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                                                          CHAPTER 3 
3.0 RESULTS 
The results presented in this chapter were based on the study objectives and the data 
analysis plan. The demographic characteristics, clinical presentation and respiratory 
pathogens in children < 5 years of age hospitalized with SARI in each hospital site were 
compared and reported. 
The risk factors for mortality were reported based on the results from the univariate and 
multivariate analysis. 
3.1 Overview 
From February 2009 through December 2013, 14901 patients with SARI were enrolled 
in the rural and urban hospital sites. Of these, 14822 (95.5%) patients had their ages 
known of which 8069 (54.2%) were children < 5 years old (Figure 1). 6583 (81.6%) of 
these patients presented at the urban hospital site while 1486 (18.4%) presented at the 
rural hospital site. In the urban site 2772/6583 (42%) were classified as sleepovers and 
were excluded from further analysis while 3811/6583 (58%) were pediatric admissions.  
A total of 5297 children < 5 years were included in the final analysis, 3811(72%) from 
the urban site and 1486 (28%) from the rural site. In the urban site, 3724 (97.7%) of 
these patients survived, 36 (0.9%) patient’s outcome were unknown and 51 (1.3%) died. 
From the rural site1372 (92.3%) survived, 11 (0.7%) had unknown outcome while 103 
(6.9%) died (Figure 1). 
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Figure 1: Flow chart of patients enrolled in the South African Severe Acute 
Respiratory Illness (SARI) surveillance program in urban and rural sites in South 
Africa, 2009 to 2013. 
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3.1.1 Demographic Characteristic 
The proportion of children aged <1 year was significantly higher in the urban (74.9%, 
2855/3811) as compared to the rural site (58.8%, 874/1486) p<0.001. In both urban and 
rural site, majority of the children with SARI were males (57.5% urban vs. 56.9% rural) 
p=0.666. The majority of patients were black at both urban (3724/3811, 97.7%) and 
rural (1479/1486, 99.5%) sites. 
The highest number of SARI admissions was in 2009 in both the urban (1031/3811, 
27.0%) and the rural (330/1486, 22.2%) sites, however, they decreased sharply in 2010 
in the urban hospital while they decreased slightly and stabilized in rural hospitals. Of all 
patients in the urban site 1386/3811 (36.4%) had record of pneumococcal vaccination of 
which 1032/1386 (74.5%) had received 2 or more doses of pneumococcal vaccine while 
in the rural site 855/1486 (57.6%) had record of pneumococcal vaccination of which 
551/855 (64.4%) had received 2 or more doses of the vaccine which is significantly 
different p<0.001. Most of the children lived in brick houses in both urban 2680/3811 
(70.3%) and rural 1419/1486 (95.5%) sites, in the urban site 1079/3811 (28.3%) of the 
patients lived in houses with iron sheeting while only 7/1486 (0.5%) patients were 
recorded living in housing with iron sheeting in the rural site. (Table 1) 
 
3.1.2 Clinical Presentation 
The proportion of patients reporting symptoms for ≥ 2 days before hospitalization was 
higher in the urban (2217/3784, 58.6%) than in the rural (668/1474, 45.3%) site 
(p<0.001). The majority of patients were administered antibiotics on admission in both 
urban (3446/3687, 93.5%) and rural (1469/1479, 99.3%) sites (p<0.001). A high 
percentage of the patients reported difficulty in breathing in both study sites 2813/3801 
(74%) in urban and 1207/1477 (81.7%) in rural (p<0.001). In the urban site 712/3800 
(18.7%) were unable to feed and drink vs. 345/1477 (23.4%) in the rural site (p<0.001). 
A higher proportion of patients in the urban site 2025/3772 (53.7%) required oxygen 
therapy compared to 312/1474 (21.2%) in the rural site (p<0.001).  
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Patients in the rural site were significantly more likely to be hospitalized for 2-7 days 
than < 2 days (1083/1466, 73.9%) compared to patients in the urban site (2305/3768, 
61.2%) p<0.001. The median duration of hospitalization in the urban site was 5 days 
(interquartile range (IQR) 1-60) while it is 5 days (IQR 0-27) in the rural site, p=0.018. 
(Table 1) 
 
TABLE 1 
Comparison of the demographic characteristics, clinical presentation and 
respiratory pathogens agents of children aged < 5 years with SARI in urban and 
rural hospital sites, South Africa 2009-2013. 
Characteristics Urban site 
N=3811  
n (%) 
Rural site 
N= 1486  
n (%) 
P value 
Demographic  
Age group 
< 1 year 
1 – 4 years 
 
2855/3811 (74.9)   
956/3811 (25.1) 
   
 
874/1486 (58.8) 
612/1486 (41.2) 
 
 
<0.001 
Sex 
Female 
Male 
 
1619/3811 (42.5) 
2192/3811 (57.5) 
 
641/1486 (43.1) 
835/1486 (56.9) 
 
0.666 
 
Race 
Black 
Other 
 
 
3724/3811 (97.7) 
87/3811 (2.3) 
 
 
1479/1486 (99.5) 
7/1486 (0.5) 
 
 
<0.001 
 
Year  
2009 
2010 
2011 
2012 
2013 
 
 
1031/3811 (27.0) 
791/3811 (20.8) 
795/3811 (20.9) 
793/3811 (20.8) 
401/3811 (10.5) 
 
 
330/1486 (22.2) 
303/1486 (20.4) 
252/1486 (17.0) 
306/1486 (20.6) 
295/1486 (19.8) 
 
 
<0.001 
 
2 or more doses of 
pneumococcal vaccine 
Yes 
No 
Missing 
 
   
 
1032/1386 (74.5) 
354/1386 (26.5) 
2425  
 
 
 
551/855 (64.4) 
304/855 (35.6) 
631  
 
 
 
<0.001 
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Type of housing 
Brick 
Iron Sheeting 
Mud 
Others 
 
2680/3811 (70.3) 
1079/3811 (28.3) 
8/3811 (0.2) 
44/3811 (1.2) 
 
1419/1484 (95.5) 
7/1486 (0.5) 
32/1486 (2.1) 
28/1486 (1.9) 
 
<0.001 
 
Number of rooms used for 
sleeping 
<2 Rooms 
≥2 Rooms 
Missing 
 
 
 
1452/3777 (38.4) 
2325/3777 (61.6) 
34  
 
   
 
169/1467 (11.5) 
1298/1467 (88.5) 
19 
 
 
 
<0.001 
 
Number of people sleeping in 
a room 
≤ 2 people 
>2 people 
Missing 
 
   
 
256/3767 (6.8) 
3511/3767 (93.2) 
44 
     
     
 
15/1466 (1.0) 
1450/1465 (99.0) 
21  
 
 
 
<0.001 
Clinical presentation  
Duration of symptoms 
<2 days prior to admission 
≥2 days prior to admission 
Missing 
 
1567/3784 (41.4) 
2217/3784 (58.6) 
27  
Median=2 days,  
*IQR(0-10) 
 
806/1474 (54.7) 
668/1474 (45.3) 
12  
Median=1 days,  
*IQR(0-7) 
 
<0.001 
 
 
<0.001 
 
Antibiotics prescribed on 
admission 
Yes 
No 
Missing 
 
 
 
3446/3687 (93.5) 
241/3687 (6.5) 
124 
 
 
 
1469/1479 (99.3) 
10/1479 (0.7) 
7 
 
 
 
<0.001 
 
Difficulty breathing 
Yes 
No 
Missing 
 
 
2813/3801 (74.0) 
988/3801 (26.0 
10 
 
 
1207/1477 (81.7) 
270/1477 (18.3) 
9 
 
 
<0.001 
    
 
Unable to drink or feed 
Yes 
No 
Missing 
 
 
712/3800 (18.7) 
3088/3800 (81.3) 
11 
 
 
345/1477 (23.4) 
1132/1477 (76.6) 
9  
 
 
<0.001 
 
Use of oxygen 
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Yes 
No 
Missing 
2025/3772 (53.7) 
1747/3772 (46.3) 
39 
312/1474 (21.2) 
1162/1474 (78.8) 
12 
<0.001 
 
 
Admission into ICU 
Yes 
No 
Missing 
 
 
 
37/3772 (1.0) 
3735/3772 (99.0) 
39 
      
 
 
0/1473 (0.0) 
1473/1473 (100.0) 
13 
 
 
 
<0.001 
 
Mechanical ventilation 
Yes 
No 
Missing 
 
 
39/3772 (1.0) 
3733/3772 (99.0) 
39 
 
 
23/1474 (1.6) 
1451/1474 (98.4) 
12 
 
 
0.113 
 
Duration of hospitalization 
<2 days 
2-7 days 
>7 days 
Missing 
 
 
406/3768 (10.8) 
2305/3768 (61.2) 
1057/3768 (28.0) 
43 
Median=5 days,  
*IQR(1-40) 
 
 
129/1466 (8.8) 
1083/1466 (73.9) 
254/1466 (17.3) 
20 
Median=5 days,  
*IQR(0-27) 
 
 
<0.001 
 
 
 
0.018 
 
TB therapy started on 
admission 
Yes 
No 
Missing 
 
   
123/3763 (3.3) 
3640/3763 (96.7) 
48 
 
     
60/1474 (4.1) 
1414/1474 (95.9) 
12 
 
 
0.155 
 
In-hospital death 
Yes 
No 
    
 
51/3811 (1.3) 
3760/3811 (98.7) 
 
 
103/1486 (6.9) 
1383/1486 (93.1) 
 
 
<0.001 
 
Underlying Medical Conditions 
 
HIV 
Positive 
Negative 
Missing 
 
257/2493 (10.3) 
2236/2493 (89.7) 
1318 
 
233/1126 (20.7) 
893/1126 (79.3) 
360 
 
<0.001 
 
Tuberculosis 
Yes 
No 
 
  
85/815 (10.4) 
730/815 (89.6) 
       
 
7/123 (5.7) 
116/123 (94.3)  
 
 
0.100 
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Missing 2996 1363 
 
 
Prematurity 
Yes 
No 
Missing 
 
Malnutrition (reported) 
Yes 
No 
Missing 
 
Malnutrition (weight for age) 
Yes 
No 
Missing 
 
Chronic lung diseases 
Yes 
No 
Missing 
 
Asthma 
Yes 
No 
Missing 
 
Renal diseases 
Yes 
No 
Missing 
 
Heart diseases 
Yes 
No 
Missing 
 
Diabetes 
Yes 
No 
Missing 
 
 
     
     
58/3806 (1.5) 
3748/3806 (98.5) 
5 
 
 
26/3806 (0.7) 
3780/380 (99.3) 
5 
 
   
209/758 (27.6) 
549/758 (72.4) 
3053 
       
 
3/3806 (0.1) 
3803/3806 (99.9) 
5 
 
 
17/3806 (0.5) 
3789/3806 (99.5) 
5 
 
       
3/3806 (0.1) 
3803/3806 (99.9) 
5 
 
 
27/3806 (0.7)       
3779/3806 (99.3) 
5 
 
 
4/3806 (0.1) 
3802/3806 (99.9) 
5 
 
 
 
 
3/1482 (0.2) 
1479/1482 (99.8) 
4 
 
 
7/1482 (0.5) 
1475/1482 (99.5) 
4 
 
 
99/451 (22.0) 
352/451 (78.0) 
1035 
 
      
0/1482 (0.0) 
1482/1482 (100.0) 
4 
 
 
12/1482 (0.8) 
1470/1482 (99.2) 
4 
 
       
0/1482 (0.0) 
1482/1482 (100.0) 
4 
 
 
0/1482 (0.0)      
1482/1482 (100.0) 
4 
 
 
0/1482 (0.0) 
1482/1482 (100.0) 
4 
 
 
 
 
<0.001 
 
 
 
 
0.382 
 
 
 
 
0.030 
 
 
 
 
0.564 
 
 
 
 
0.108 
 
 
 
 
0.564 
 
 
 
 
<0.001 
 
 
 
 
0.582 
 
 
 
 
 30 
 
Neurological diseases 
Yes 
No 
Missing 
    
11/3806 (0.3) 
3795/3806 (99.7) 
5 
       
8/1482 (0.5) 
1474/1482 (99.5) 
4 
0.171 
 
Respiratory pathogens 
Influenza 
Yes 
No 
Missing 
 
Adenovirus 
Yes 
No 
Missing 
 
Enterovirus 
Yes 
No 
Missing 
 
Rhinovirus  
Yes 
No 
Missing 
 
Respiratory syncytial virus 
Yes 
No 
Missing 
 
Human metapneumovirus  
Yes 
No 
Missing 
 
Parainfluenza virus 1 
Yes 
No 
Missing 
 
Parainfluenza virus 2 
Yes 
 
 
 
227/3709 (6.1) 
3482/3709 (93.9) 
102 
 
 
779/3461 (22.5) 
2682/3461 (77.5) 
350 
 
 
344/3708 (9.3) 
3364/3708 (90.7) 
103 
 
 
1219/3708 (32.9) 
2489/3708 (67.1) 
103 
 
 
1010/3708 (27.2) 
2698/3708 (72.8) 
103 
 
 
209/3708 (5.6) 
3499/3708 (94.4) 
103 
 
 
64/3708 (1.7) 
3644/3708 (98.3) 
103 
 
 
40/3708 (1.1) 
 
 
 
118/1426 (8.3) 
1308/1426 (91.7) 
60 
 
 
323/1304 (24.8) 
981/1304 (75.2) 
182 
 
 
139/1426 (9.4) 
1287/1426 (90.6) 
60 
 
 
495/1426 (34.7) 
931/1426 (65.3) 
60 
 
 
246/1426 (17.3) 
1180/1426 (82.7) 
60 
 
 
75/1426 (5.3) 
1351/1426 (94.7) 
60 
 
 
17/1426 (1.2) 
1409/1426 (98.8) 
60 
 
 
23/1426 (1.6) 
 
 
 
0.006 
 
 
 
 
0.099 
 
 
 
 
0.605 
 
 
 
 
0.211 
 
 
 
 
<0.001 
 
 
 
 
0.597 
 
 
 
 
0.169 
 
 
 
 
0.119 
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No 
Missing 
 
Parainfluenza virus 3 
Yes 
No 
Missing 
 
Parainfluenza virus 1,2 or 3 
Yes 
No 
Missing 
 
Any respiratory virus  
Yes 
No 
Missing 
 
More than 1 respiratory virus 
Yes 
No 
Missing 
 
Pneumococcal infection on 
lytA PCR 
Yes 
No 
Missing 
 
Blood culture done 
Yes 
No 
 
**Relevant bacterial infection 
on blood culture 
Yes 
No 
Missing 
 
Co-infection with 
pneumococcus and influenza 
Yes 
No 
3668/3708 (98.9) 
103 
 
 
230/3708 (6.2) 
3478/3708 (93.8) 
103 
 
 
327/3708 (8.8) 
3381/3708 (91.2) 
103 
 
 
2878/3709 (77.6) 
831/3709 (22.4) 
102 
 
 
1253/3709 (33.8) 
2456/3709 (66.2) 
102 
 
 
   
113/1592 (7.1) 
1479/1592 (92.9) 
2219 
 
 
2189/3811 (57.4) 
1622/3811 (42.6) 
 
   
   
50/2189 (2.3)     
2139/2189 (97.7) 
1622 
 
 
 
17/1393 (1.2) 
1375/1393 (98.8) 
1403/1426 (98.4) 
60 
 
 
90/1426 (6.3) 
1336/1426 (93.7) 
60 
 
 
127/1426 (8.9) 
1299/1426 (91.1) 
60 
 
 
1082/1426 (75.9) 
344/1426 (24.1) 
60 
 
 
467/1426 (32.7) 
959/1426 (67.3) 
60 
 
 
     
53/1211 (4.4) 
1158/1211 (95.6) 
275 
 
 
39/1486 (2.6) 
1447/1486 (97.4) 
 
   
       
0/39 (0.0) 
39/39 (100.0) 
1447 
 
 
 
3/1063 (0.3) 
1060/1063 (99.7) 
 
 
 
 
0.885 
 
 
 
 
0.921 
 
 
 
 
0.189 
 
 
 
 
0.482 
 
 
 
 
 
0.002 
 
 
 
 
<0.001 
 
 
 
 
1.000 
 
 
 
 
 
0.011 
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Missing 2419 423  
 
 * IQR=interquartile range 
** Column percentage were calculated as a percent of all those with available data for the variable (i.e. 
not including missing) 
** The relevant invasive bacterial infections are Streptococcus pneumoniae, Haemophilus influenzae, 
Klebsiella pneumoniae, Staphylococcus aureus, Neisseria meningitidis, Escherichia coli, Streptococcus 
agalactiae or group b streptococcus, Pseudomonas aerugenosa and Salmonella species. 
 
 
3.1.3 Underlying Medical Conditions  
Information on HIV infection status was available for 3619 (68.3%) children overall with 
1678 (31.7%) missing. The HIV prevalence in the urban site was significantly lower 
10.3% (257/2493) than in the rural site 20.7% (233/1126), p<0.001. In the urban site 
more children were newly diagnosed with tuberculosis 85/815 (10.4%) compared to the 
rural site of 7/123 (5.7%). Prematurity (58/3806 (1.5%) in urban with 3/1482 (0.2%) in 
rural p<0.001) and underlying heart disease (27/3802 (0.7%) in the urban site and none 
in the rural site, p<0.001) were more commonly reported in the urban site. A similar 
percent of children were reported malnourished in the urban and rural sites (26/3806 
(0.7%) in urban with 7/1482 (0.5%) in rural, p=0.382). Malnutrition was further assessed 
by estimating the weight for age which was calculated using the WHO z score chart for 
1209/5297 (22.8%) of individuals for whom weight data were available. A significant 
higher proportion were assessed to be malnourished in the urban site (209/758, 27.6%) 
as compared to the rural site (99/451, 22.0%) (p=0.03). (Table 1) 
 
3.1.4 Respiratory pathogens 
Overall 5135/5297 (96.9%) of children were tested for respiratory viruses, influenza was 
detected more commonly in the rural (118/1426, 8.3%) than in the urban (227/3709, 
6.1%) (p=0.006). 
RSV was detected more in the urban (1010/3708, 27.2%) than in the rural (246/1426, 
17.3%) p < 0.001. A similar percentage of children had at least one respiratory virus in 
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both study sites (2878/3709, (77.6%) in urban with 1082/1426, (75.9%) in rural, 
p=0.189).  
Overall 2803/5297 (52.9%) children were tested for blood pneumococcal on lytA PCR of 
which a significantly higher proportion of those positive were recorded in urban 
(113/1592, 7.1%) compared to rural (53/1211, 4.4%), (p=0.002). Total number of 
children that had blood culture were 2189/3811 (35.9%) in urban vs. 39/1486 (2.6%) in 
rural, (p<0.001), with 50/2189 (2.3%) testing positive for relevant bacterial infection in 
urban and 0/39 (0%) testing positive in the rural site, (p=1.000). (Table 1) 
 
 
3.2 Case-fatality proportion (CFP) 
The overall CFP in this study was 2.9% (154/5297).The CFP was significantly higher in 
the rural (103/1486, 6.9%) than the urban (51/3811, 1.3%) p< 0.001. This was observed 
among both HIV-infected [urban 6.6% (17/257) vs. rural 12.9% (30/233), (p=0.019)] and 
HIV-uninfected [urban 0.6% (13/2236) vs. rural 4.2% (36/857), (p<0.001)] children. 
(Tables 2 and 3) 
 
3.3.1 Univariate analysis of risk factors associated with mortality in the urban site 
The variables found to be significantly associated with in-hospital mortality in the urban 
site on univariate analysis using binary logistic regression at p<0.1 were HIV, race, year, 
difficulty in breathing, use of oxygen, duration of hospitalization, chronic lung disease, 
rhino virus, RSV, any respiratory virus, blood culture and invasive relevant bacterial 
infection on culture (Table 2). 
 
3.3.2 Multivariate analysis of variables associated with in-hospital mortality in the 
urban site 
A total of 2475 children from urban site with complete data were included in the 
multivariable analysis. In the urban site the only factor independently associated with 
death on multivariate analysis was HIV infection (OR 12.1, 95% CI 5.8-25.2). (Table 2) 
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Table 2: Factors associated with In-Hospital death in children < 5 years of age 
with SARI, in Urban Hospital Site, South Africa, 2009–2013. 
 
Characteristics Hospitalized 
Case Fatality 
Proportion 
Univariate 
analysis 
OR (95%CI) 
P value Multivariable 
analysis 
OR (95%CI) 
P value 
Demographic   
Age group 
< 1 year 
1 – 4 years 
 
42/2855 (1.5%) 
9/956 (0.94%) 
 
1.6 (0.8-3.2) 
Reference 
 
0.200 
 
 
- 
 
- 
 
Sex 
Female 
Male 
 
 
26/1619 (1.6%) 
25/2192 (1.1%) 
 
 
1.4 (0.8-2.5) 
Reference 
 
 
0.219 
 
 
- 
 
 
- 
 
Race 
Black 
Other 
 
 
45/3724 (1.2%) 
6/87 (6.9%) 
 
 
Reference 
6.1 (2.5-14.6) 
 
 
0.020 
 
 
NS 
 
 
NS 
 
Year  
2009 
2010 
2011 
2012 
2013 
 
 
15/1031 (1.5%) 
21/791 (2.7%) 
7/795 (0.9%) 
6/793 (0.8%) 
2/401 (0.5%) 
 
 
Reference 
1.8 (0.9-3.6) 
0.6 (0.2-1.5) 
0.5 (0.2-1.3) 
0.3 (0.1-1.5) 
 
 
0.005 
 
 
NS 
 
 
NS 
 
2 or more doses of 
pneumococcal vaccine 
Yes 
No 
 
 
 
 
18/1032 (1.7%) 
7/354 (2%) 
 
 
 
 
Reference 
1.1 (0.5-2.7) 
 
 
 
 
0.778 
 
 
 
 
- 
 
 
 
 
- 
 
Type of housing 
Brick 
Iron Sheeting 
Mud 
Others 
 
 
35/2680 (1.3%) 
14/1079 (1.3%) 
0/8 (0%) 
2/44 (4.6%) 
 
 
Reference 
1.0 (0.5-1.9) 
Undefined 
3.6 (0.8-15.5) 
 
 
0.341 
 
 
- 
 
 
- 
 
 
Number of rooms used 
for sleeping 
<2 Rooms 
≥2 Rooms 
 
 
 
22/1452 (1.5%) 
28/2325 (1.2%) 
 
 
 
1.3 (0.7-2.2) 
Reference 
 
 
 
0.420 
 
 
 
- 
 
 
 
- 
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Number of people 
sleeping in a room 
≤2 people 
>2 people 
 
   
4/256 (1.6%) 
46/3511 (1.3%) 
 
 
1.2 (0.4-3.3) 
Reference 
 
 
0.739 
 
 
- 
 
 
- 
 
Clinical presentation 
Duration of symptoms 
<2 days prior to 
admission 
≥2 days prior to 
admission 
 
 
17/1567 (1.1%) 
 
33/2217 (1.5%) 
 
 
Reference 
 
1.4 (0.8-2.5) 
 
 
0.279 
 
 
- 
 
 
- 
 
Difficulty breathing 
Yes 
No 
 
 
43/2813 (1.5%) 
7/988 (0.7%) 
 
 
2.2 (1.0-4.9) 
Reference 
 
 
0.04 
 
 
NS 
 
 
NS 
      
 
Unable to drink or feed 
Yes 
No 
 
 
13/712 (1.8%) 
37/3088 (1.2%) 
 
 
1.5 (0.8-2.9) 
Reference 
 
 
0.204 
 
 
- 
 
 
- 
 
Antibiotics prescribed 
on admission 
Yes 
No 
 
 
 
48/3446 (0.8%) 
5/241 (0.8%) 
 
 
 
Reference 
1.6 (0.6-4.1) 
 
 
 
0.352 
 
 
 
- 
 
 
 
- 
  
Use of oxygen 
Yes 
No 
 
 
43/2025 (2.1%) 
7/1747 (0.4%) 
 
 
5.4 (2.4-12.0) 
Reference 
 
 
<0.0001 
 
 
NE 
 
 
 
NE 
 
 
Admission into ICU 
Yes 
No 
 
 
0/37 (0%) 
50/3735 (1.3%) 
 
 
Undefined 
Reference 
 
     
    - 
 
 
- 
 
 
- 
 
Mechanical ventilation 
Yes 
No 
 
 
0/39 (0%) 
50/3733 (1.3%) 
 
 
Undefined 
Reference 
 
    
    - 
 
 
- 
 
 
- 
 
Duration of 
hospitalization 
<2 days 
2-7 days 
>7 days 
 
 
 
4/406 (1%) 
25/2305 (1.1%) 
22/1057 (2.1%) 
 
 
 
Reference 
1.1 (0.4-3.2) 
2.1 (0.7-6.2) 
 
 
 
0.07 
 
 
 
NS 
 
 
 
NS 
 
TB therapy started on 
admission 
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Yes 
No 
3/123 (2.4%) 
47/3640 (1.3%) 
1.9 (0.6-6.2) 
Reference 
0.325 - - 
 
Underlying medical conditions 
HIV 
Positive 
Negative  
 
17/257 (6.6%) 
13/2236 (0.6%) 
 
12.1 (5.8-25.2) 
Reference 
 
<0.0001 
 
12.1 (5.8-25.2) 
Reference 
 
<0.001 
 
 
Tuberculosis 
Yes 
No 
 
 
 
2/85 (2.4%) 
13/730 (1.8%) 
 
 
 
1.3 (0.3-6.0) 
Reference 
 
 
 
0.720 
 
 
 
- 
 
 
 
- 
 
Prematurity 
Yes 
No 
 
Malnutrition (reported) 
Yes 
No 
 
 
Malnutrition   
(weight for age) 
Yes 
No 
 
Chronic lung diseases 
Yes 
No 
 
Asthma 
Yes 
No 
 
Renal diseases 
Yes 
No 
 
Heart diseases 
Yes 
No 
 
Diabetes 
Yes 
 
1/58 (1.7%) 
49/3748 (1.3%) 
 
 
1/26 (3.9%) 
49/3780 (1.3%) 
 
 
 
 
3/209 (1.4%) 
1/548 (0.2%) 
 
 
1/3 (33.3%) 
49/3803 (1.3%) 
 
 
0/17 (0%) 
50/3789 (1.3%) 
 
 
0/3 (0%) 
50/3803 (1.3%) 
 
 
0/32 (0%) 
50/3779 (1.3%) 
 
 
0/4 (0%) 
53/3802 (1.3%) 
 
1.3 (0.2-9.8) 
Reference 
 
 
3.0 (0.4-22.9) 
Reference 
 
 
 
 
3.0 (0.4-22.9) 
Reference 
 
 
38.3 (3.4-429.4) 
Reference 
 
 
Undefined 
Reference 
 
 
Undefined 
Reference 
 
 
Undefined 
 
 
 
Undefined 
 
 
0.792 
 
 
 
0.354 
 
 
 
 
 
0.279 
 
 
 
0.027 
 
 
 
    - 
 
 
 
     - 
 
 
 
       - 
 
 
 
        - 
 
 
- 
 
 
 
- 
 
 
 
 
 
- 
 
 
 
NS 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
- 
 
 
 
- 
 
 
 
 
 
- 
 
 
 
NS 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
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No 
 
Neurological diseases 
Yes 
No 
 
 
 
1/11 (9.1%) 
49/3795 (1.3%) 
 
 
7.6 (1.0-60.9) 
Reference 
 
 
0.134 
 
 
- 
 
 
- 
 
Respiratory pathogen   
Influenza 
Yes 
No 
 
Adenovirus 
Yes 
No 
 
Enterovirus 
Yes 
No 
 
Rhinovirus  
Yes 
No 
 
Respiratory syncytial 
virus 
Yes 
No 
 
Human 
metapneumovirus  
Yes 
No 
 
Parainfluenza virus 1 
Yes 
No 
 
Parainfluenza virus 2 
Yes 
No 
 
Parainfluenza virus 3 
Yes 
No 
 
Parainfluenza virus 1,2 
 
 
4/227 (1.8%) 
46/3482 (1.3%) 
 
 
12/779 (1.5%) 
36/2682 (1.3%) 
 
 
5/344 (1.5%) 
45/3364 (1.3%) 
 
 
11/1219 (0.9%) 
39/2489 (1.6%) 
 
 
 
8/1010 (0.8%) 
42/2698 (1.6%) 
 
 
 
2/209 (1.0%) 
48/3499 (1.4%) 
 
 
1/64 (1.6%) 
49/3644 (1.3%) 
 
 
1/40 (2.5%) 
49/3668 (1.3%) 
 
 
4/230 (1.7%) 
46/3478 (1.3%) 
 
 
 
 
1.3 (0.5-3.8) 
Reference 
 
 
Reference 
0.9 (0.5-1.7)  
 
 
1.1 (0.4-2.8) 
Reference 
 
 
Reference 
1.7 (0.9-3.4) 
 
 
 
Reference 
2.0 (0.9-4.2) 
 
 
 
Reference 
1.4 (0.3-6.0) 
 
 
1.2 (0.2-8.6) 
Reference 
 
 
1.9 (0.3-14.1) 
Reference 
 
 
1.3 (0.5-3.7) 
Reference 
 
 
 
 
0.593 
 
 
 
0.681 
 
 
 
0.861 
 
 
 
0.09 
 
 
 
 
0.058 
 
 
 
 
0.595 
 
 
 
0.8838 
 
 
 
0.570 
 
 
 
0.611 
 
 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
NS 
 
 
 
 
NS 
 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
NS 
 
 
 
 
NS 
 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
 38 
 
or 3 
Yes 
No 
 
Any respiratory virus  
Yes 
No 
 
More than 1 respiratory 
virus 
Yes 
No 
 
Pneumococcal infection 
on lytA PCR 
Yes 
No 
 
Blood culture done 
Yes 
No 
 
**Relevant bacterial 
infection on blood 
culture 
Yes 
No 
 
Co-infection with 
pneumococcus and 
influenza  
Yes 
No 
 
5/327 (1.5%) 
45/3381 (1.3%) 
 
 
33/2878 (1.2%) 
17/831 (2.1%) 
 
 
 
19/1253 (1.5%) 
31/2456 (1.3%) 
 
 
 
1/113 (0.9%) 
15/1479 (1.0%) 
 
 
36/2189 (1.6%) 
15/1622 (0.9%) 
 
 
 
 
1/50 (2%) 
35/2139 (1.6%) 
 
 
   
   
0/17 (0%) 
15/1375 (1.1%) 
 
1.2 (0.5-2.9) 
Reference 
 
 
Reference 
1.8 (1.0-3.2) 
 
 
 
Reference 
0.8 (0.5-1.5) 
 
 
 
0.9(0.1-6.7) 
Reference 
 
 
1.8 (1.0-3.3) 
Reference 
 
 
 
 
1.2 (0.2-9.1) 
Reference 
 
 
 
 
Undefined 
 
0.771 
 
 
 
0.060 
 
 
 
 
0.529 
 
 
 
 
0.892 
 
 
 
0.05 
 
 
 
 
 
0.04 
 
 
  
       
  
- 
 
- 
 
 
 
NS 
 
 
 
 
- 
 
 
 
 
- 
 
 
 
NE 
 
 
 
 
 
NE 
 
 
 
 
 
- 
 
- 
 
 
 
NS 
 
 
 
 
- 
 
 
 
 
- 
 
 
 
NE 
 
 
 
 
 
NE 
 
 
 
 
 
- 
  
 Variables statistically significant on univariate and multivariate logistic regression analysis 
presented in boldface. 
 Variables not statistically significant on univariate logistic regression (p>0.1) were omitted from 
the multivariable logistic regression model. 
 NE (Not evaluated): variables statistically significant on univariate analysis but omitted in the 
multivariate analysis. 
 NS (Not significant): variables not statistically significant on multivariate analysis (p≥0.05) 
** The relevant invasive bacterial infections are Streptococcus pneumoniae, Haemophilus influenzae, 
Klebsiella pneumoniae, Staphylococcus aureus, Neisseria meningitidis, Escherichia coli, 
Streptococcus agalactiae or group b streptococcus, Pseudomonas aerugenosa and 
Salmonella species. 
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3.3.3 Univariate analysis of risk factors associated with mortality in the rural site 
The variables found to be significantly associated with in-hospital mortality in the rural 
site on univariate analysis using binary logistic regression at p<0.1 were HIV, age-
group, sex, unable to drink or feed, use of oxygen, mechanical ventilation, duration of 
hospitalization, malnutrition (weight for age), adenovirus, RSV, any respiratory virus, 
more than 1 respiratory virus, pneumococcal infection and blood culture. (Table 3) 
 
3.3.4 Multivariate analysis of variables associated with in-hospital mortality in the 
rural site 
A total of 1029 from the rural site with complete data were included in multivariable 
analysis. In the rural site HIV infection (OR 3.5, 95%CI 1.7-6.9), age <1 year (OR 3.5, 
95% CI 2.0-6.1) vs. 1-4 years, malnutrition (OR 12.8, 95%CI 1.2-134.6) and 
pneumococcal infection on lytA PCR (OR 4.5, 95% CI 1.8-10.8) were independently 
associated with increased risk of mortality. Individuals with respiratory virus detected 
were less likely to die (OR 0.4, 95%CI 0.2-0.6). (Table 3) 
 
Table 3:  
Factors associated with In-Hospital death in children < 5 years of age with SARI, 
in Rural Hospital Site, South Africa, 2009–2013. 
 
Characteristics 
 
Hospitalized 
Case Fatality 
Proportion 
Univariate 
analysis 
OR (95%CI) 
P value Multivariable 
analysis 
OR (95%CI) 
P value 
Demographic   
Age group 
< 1 year 
1 – 4 years 
 
82/874 (9.4%) 
21/612 (3.4%) 
   
 
2.9 (1.8-4.8) 
Reference 
 
 
<0.0001 
 
3.5 (2.0-6.1) 
Reference 
 
<0.001 
Sex 
Female 
Male 
 
60/641 (9.3%) 
43/845 (5.1%) 
 
1.9 (1.3-2.9) 
Reference 
 
0.002 
 
NS 
 
NS 
 
 
Race 
Black 
Other 
 
 
102/1377 (7.4%) 
1/7 (14.3%) 
 
 
Reference 
2.3 (0.3-18.9) 
 
 
0.497 
 
 
- 
 
 
- 
 
Year  
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2009 
2010 
2011 
2012 
2013 
18/330 (5.5%) 
29/303 (9.6%) 
21/252 (8.3%) 
18/306 (5.9%) 
17/295 (5.8%) 
Reference 
1.8 (1.0-3.4) 
1.6 (0.8-3.0) 
1.1 (0.6-2.1) 
1.1 (0.5-2.1) 
0.193 - - 
 
2 or more doses of 
pneumococcal vaccine 
Yes 
No 
 
 
 
31/551 (5.6%) 
26/304 (8.6%) 
 
 
 
Reference 
1.6 (0.9-2.7) 
 
 
 
 
0.106 
 
 
 
 
- 
 
 
 
 
- 
 
Type of housing 
Brick 
Iron Sheeting 
Mud 
Others 
 
 
97/1419 (6.8%) 
0/7 (0%) 
2/32 (6.3%) 
4/28 (14.3%) 
 
 
Reference 
Undefined 
0.9 (0.2-3.9) 
2.2 (0.05-0.1) 
 
 
0.391 
 
 
- 
 
 
- 
 
Number of rooms used 
for sleeping 
<2 Rooms 
≥2 Rooms 
 
 
 
17/169 (1.0%) 
84/1298 (6.5%) 
 
 
 
1.6 (0.9-2.8) 
Reference 
 
 
 
0.100 
 
 
 
- 
 
 
 
- 
 
 
Number of people 
sleeping in a room 
≤2 people 
>2 people 
 
 
     
 
1/15 (6.7%) 
100/1450 (6.9%) 
 
 
 
 
1.0 (0.1-7.4) 
Reference 
 
 
 
 
0.972 
 
 
 
 
- 
 
 
 
 
- 
 
Clinical presentation 
   
Duration of symptoms 
<2 days prior to 
admission 
≥2 days prior to 
admission 
 
 
51/806 (6.3%) 
 
51/668 (7.6%) 
 
 
Reference 
 
1.2 (0.8-1.8) 
 
 
0.326 
 
 
- 
 
 
- 
 
Difficulty breathing 
Yes 
No 
 
 
90/1207 (7.5%) 
13/270 (4.8%) 
 
 
1.6 (0.9-2.9) 
Reference 
 
 
0.108 
 
 
- 
 
 
- 
      
 
Unable to drink or feed 
Yes 
No 
 
 
34/345 (9.9%) 
69/1132 (6.1%) 
 
 
1.7 (1.1-2.6) 
Reference 
 
 
0.021 
 
 
NS 
 
 
NS 
 
Antibiotics prescribed 
on admission 
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Yes 
No 
101/1469 (6.9%) 
2/10 (20%) 
Reference 
3.4 (0.7-16.2) 
0.177 - - 
 
Use of oxygen 
Yes 
No 
 
 
83/312 (26.6%) 
20/1162 (1.7%) 
 
 
20.7(12.4-34.4) 
Reference 
 
 
<0.0001 
 
 
NE 
 
 
 
NE 
 
 
Admission into ICU 
Yes 
No 
 
 
0/0 (0%) 
103/1473 (7%) 
 
 
Undefined 
Omitted 
 
       
- 
 
 
- 
 
 
- 
 
Mechanical ventilation 
Yes 
No 
 
 
19/23 (82.6%) 
84/1451 (5.8%) 
 
 
77.3(25.7-232.3) 
Reference 
 
 
<0.0001 
 
 
NE 
 
 
NE 
 
Duration of 
hospitalization 
<2 days 
2-7 days 
>7 days 
 
 
 
18/129 (14%) 
62/1083 (5.7%) 
22/254 (8.7%) 
 
 
 
Reference 
0.4 (0.2-0.7) 
0.6 (0.3-1.1) 
 
 
 
0.003 
 
 
 
NS 
 
 
 
 
NS 
 
 
 
Tuberculosis therapy 
started on admission 
Yes 
No 
 
 
   
4/60 (6.7%) 
99/1414 (7%) 
 
 
 
0.9 (0.3-2.7) 
Reference 
 
 
 
0.9201 
 
 
 
- 
 
 
 
- 
Underlying medical conditions 
HIV 
Positive 
Negative  
 
30/233 (12.9%) 
36/857 (4.2%) 
 
3.5 (2.1-5.8) 
Reference 
 
<0.0001 
 
3.5 (1.7-6.9) 
Reference 
 
<0.001 
 
Tuberculosis 
Yes 
No 
 
 
2/7 (28.6%) 
6/116 (5.2%) 
 
 
7.3 (1.2-45.9) 
Reference 
 
 
0.058 
 
 
NS 
 
 
NS 
 
Prematurity 
Yes 
No 
 
Malnutrition (reported) 
Yes 
No 
 
Malnutrition   
(weight for age) 
Yes 
No 
 
 
0/3 (0%) 
102/1479 (6.9%) 
 
 
3/7 (42.9%) 
99/1475 (6.7%) 
 
 
      
12/99 (12.1%) 
14/352 (4.0%) 
 
 
Undefined 
Reference 
 
 
10.4 (2.3-47.2) 
Reference 
 
 
 
1.2 (0.4-2.0) 
Reference 
 
 
- 
 
 
 
0.008 
 
 
 
 
 0.005 
 
 
 
           - 
 
 
 
12.8 (1.2-134.6) 
Reference 
 
 
 
NE 
 
 
 
      - 
 
 
 
0.034 
 
 
 
 
NE 
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Chronic lung diseases 
Yes 
No 
 
Asthma 
Yes 
No 
 
Renal diseases 
Yes 
No 
 
Heart diseases 
Yes 
No 
 
Diabetes 
Yes 
No 
 
Neurological diseases 
Yes 
No 
 
 
0/0 (0%) 
102/1380 (7.4%) 
 
 
0/12 (0%) 
102/1470 (6.9%) 
 
 
0/0 (0%) 
102/1482 (6.9%) 
 
 
 0/0 (0%) 
102/1482 (6.9%) 
 
 
 0/0 (0%)    
102/1482 (6.9%) 
 
 
1/8 (12.5%) 
101/1474 (6.9%) 
 
 
Undefined 
Reference 
 
 
Undefined 
Reference 
 
 
Undefined 
Reference 
 
 
Undefined 
Reference 
 
 
Undefined 
Reference 
 
 
1.9 (0.2-15.9) 
Reference 
 
 
 
   - 
 
 
    - 
 
 
 
    - 
 
 
 
    - 
 
 
 
    - 
 
 
 
0.569 
 
 
 
- 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
Respiratory 
pathogens    
Influenza 
Yes 
No 
 
Adenovirus 
Yes 
No 
 
Enterovirus 
Yes 
No 
 
Rhinovirus  
Yes 
No 
 
Respiratory syncytial 
virus 
Yes 
 
 
 
 
4/118 (3.4%) 
86/1308 (6.6%) 
 
 
12/323 (3.7%) 
67/981 (6.8%) 
 
 
9/139 (6.5%) 
81/1287 (6.3%) 
 
 
30/495 (6.1%) 
60/931 (6.4%) 
 
 
 
5/246 (2.0%) 
 
 
 
 
0.5 (0.2-1.4) 
Reference 
 
 
Reference 
1.9 (1.0-3.6)   
 
 
1.0 (0.5-2.1)  
Reference 
 
 
Reference 
1.1 (0.7-1.7) 
 
 
 
Reference 
 
 
 
 
0.140 
 
 
 
0.032 
 
 
 
0.934 
 
 
 
0.776 
 
 
 
 
0.001 
 
 
 
 
- 
 
 
 
NS 
 
 
 
- 
 
 
 
- 
 
 
 
 
NS 
 
 
 
 
- 
 
 
 
NS 
 
 
 
- 
 
 
 
- 
 
 
 
 
NS 
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No 
 
Human 
metapneumovirus  
Yes 
No 
 
Parainfluenza virus 1 
Yes 
No 
 
Parainfluenza virus 2 
Yes 
No 
 
Parainfluenza virus 3 
Yes 
No 
 
Parainfluenza virus 1,2 
or 3 
Yes 
No 
 
Any respiratory virus  
Yes 
No 
 
More than one 
respiratory virus 
Yes 
No 
 
Pneumococcal 
infection on lytA PCR 
Yes 
No 
 
Blood culture done 
Yes 
No 
 
 
**Relevant bacterial 
infection on blood 
culture 
85/1180 (7.2%) 
 
 
 
2/75 (2.75) 
88/1351 (6.5%) 
 
 
1/17 (5.9%) 
89/1409 (6.3%) 
 
 
1/23 (4.3%) 
89/1403 (6.3%) 
 
 
5/90 (5.6%) 
85/1336 (6.4%) 
 
 
 
7/127 (5.5%) 
83/1299 (6.4%) 
 
 
55/1082 (5.1%) 
35/344 (10.2%) 
 
 
 
20/467 (4.3%) 
70/959 (7.3%) 
 
 
   
8/53 (15.1%) 
66/1158 (5.7%) 
 
 
11/39 (28.2%) 
92/1447 (6.4%) 
 
 
  
 
 
3.7 (1.5-9.3) 
 
 
 
Reference 
2.5 (0.6-10.5) 
 
 
0.9 (0.1-7.1) 
Reference 
 
 
0.7 (0.1-5.0) 
Reference 
 
 
0.9 (0.3-2.2) 
Reference 
 
 
 
0.9 (0.4-1.9) 
Reference 
 
 
0.5 (0.3-0.8) 
Reference 
 
 
 
Reference 
1.8 (1.1-2.9) 
 
 
 
2.9 (1.3-6.5) 
Reference 
 
 
5.8 (2.8-12.0) 
Reference 
 
 
 
 
 
 
 
 
 
0.136 
 
 
 
0.941 
 
 
 
0.680 
 
 
 
0.756 
 
 
 
 
0.692 
 
 
 
0.001 
 
 
 
 
0.023 
 
 
 
 
0.016 
 
 
 
<0.0001 
 
 
 
 
 
 
 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
 
- 
 
 
 
0.4 (0.2-0.6) 
   Reference 
 
 
 
NS 
 
 
 
 
4.5 (1.8-10.8) 
Reference 
 
 
NE 
 
 
 
 
 
 
 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
 
- 
 
 
 
<0.001 
 
 
 
 
NS 
 
 
 
 
0.001 
 
 
 
NE 
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Yes 
No 
 
Co-infection with 
pneumococcus and 
influenza 
Yes 
No 
Empty 
11/39 (28.2%) 
 
 
  
 
0/3 (0%) 
64/1060 (6%) 
Omitted 
Reference 
 
 
 
 
Undefined 
Reference 
      - 
 
 
 
      
      
        - 
- 
 
 
 
 
 
- 
- 
 
 
 
 
 
- 
 
  
* Variables statistically significant on univariate and multivariate logistic regression analysis 
presented in boldface. 
* Variables not statistically significant on univariate logistic regression (p>0.1) were omitted 
from the multivariable logistic regression model. 
* NE (Not evaluated): variables statistically significant on univariate analysis but omitted in the 
multivariate analysis. 
* NS (Not significant): variables not statistically significant on multivariate analysis (p≥0.05) 
** The relevant invasive bacterial infections are Streptococcus pneumoniae, Haemophilus 
influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Neisseria meningitidis, Escherichia 
coli, Streptococcus agalactiae or group b streptococcus, Pseudomonas aerugenosa and 
Salmonella species 
 
 
 
 
3.4.1 Characteristics of children who died  
Amongst children who died, the proportion of children aged <1 year was not significantly 
different in both hospital sites (42/51 (82.4%) in urban and 82/103 (79.6%) in rural, 
p=0.686. In both urban and rural sites majority of the children who died were females 
(26/51 (51.0%) urban vs. 60/103 (58.3%) rural, p=0.392). The highest number of 
children that died was recorded in 2010 in both urban (21/51, 41.2%) and rural (29/103, 
28.1%) sites. Of all the children that died in the urban site 18/25 (72.0%) had received 2 
or more doses of pneumococcal vaccine while in the rural site (31/57 (54.4%) p=0.134) 
had received PCV. Most of the children who died lived in brick houses in both urban 
35/51 (68.6%) and rural 97/103 (94.2%) sites, p<0.001. (Table 4) 
The proportion of children that died reporting symptoms for ≥ 2 days before 
hospitalization was higher in the urban (33/50, 66.0%) than in the rural (51/102, 50.0%) 
site, (p=0.062). The majority of the children that died were administered antibiotics on 
admission in both urban (45/50, 90.0%) and rural (101/102, 98.1%) sites, but 
significantly higher in the rural site (p=0.025). A high percentage of children who died 
reported difficulty in breathing in both study sites 43/50 (86.0%) in urban and 90/103 
 45 
 
(87.4%) in rural (p=0.812). Children that died in the rural site were significantly more 
likely to be hospitalized for 2-7 days (62/102, 60.8%) compared to those in the urban 
site (25/51, 49.0%) p=0.014. The average time of hospitalization was shorter for 
children who died in the rural site 3 days (IQR 0-26) than in the urban site (5 days (IQR 
1-59), p=0.013). (Table 4) 
The HIV prevalence in the urban site amongst children who died was higher in urban 
than in rural site although this was not statistically significant, 57.7% (17/30) vs. 45.5% 
(30/66), p=0.308. A similar percent of children who died were reported malnourished in 
the urban and rural sites (1/50 (2.0%) in urban with 3/102 (2.9%) in rural, p=0.733). 
Assessing malnutrition by calculating the weight for age there was no significant 
difference in both sites for children that died (urban 3/4 (75.0%) and rural 12/26 
(46.2%), p=0.598. (Table 4) 
Overall 140/154 (90.9%) of children who died were tested for respiratory viruses, 
influenza was detected more commonly in the urban (4/50, 8.0%) than in the rural (4/90, 
4.4%) (p=0.385). RSV was detected more in the urban (8/50, 16.0%) than in the rural 
(5/90, 5.6%) (p=0.041). More than one respiratory virus was detected more amongst 
children who died in the urban (19/50, 38.0%) than in the rural (20/90, 22.2%) 
(p=0.046), (Table 4). Amongst children who died, 90/154 (58.4%) were tested for blood 
pneumococcal on lytA PCR of which a higher proportion of those positive were recorded 
in rural (8/74, 10.8%) compared to urban (1/16, 6.3%), (p=0.581).  
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Table 4: Demographic characteristics, clinical presentation and respiratory 
pathogens with factors associated with hospital site (rural vs. urban) among 
children < 5 years of age with SARI who died in hospital, South Africa, 2009–2013. 
Characteristics Urban site 
N=51 
n (%) 
Rural Site 
N= 103  
n (%) 
Univariate 
analysis  
OR (95%CI) 
P 
value 
Multivariable 
analysis 
OR (95%CI) 
P 
value 
Demographic 
Age Group < 1 year 
 
42/51 (82)   
 
82/103 (80) 
 
0.8 (0.4-2.0) 
 
0.686 
 
- 
 
- 
Female gender 26/51 (51) 60/103 (58) 0.7 (0.4-1.5) 0.392 - - 
Black race 45/51 (88) 102/103 (99) 13.6 (1.6-116.3) 0.002 NS NS 
Year  
2009 
2010 
2011 
2012 
2013 
 
15/51 (29) 
21/51 (41) 
7/51 (14) 
6/51 (12) 
2/51 (4) 
 
18/103 (18) 
29/103 (28) 
21/103 (20) 
18/103 (18) 
17/103 (16) 
 
Reference 
1.2 (0.4-2.8) 
2.5 (0.8-7.5) 
2.5 (0.8-7.9) 
7.1 (1.4-35.7) 
 
0.041 
 
NS 
 
NS 
2 or more doses of 
pneumococcal vaccine 
 
18/25 (72) 
 
31/57 (54) 
 
0.5 (0.2-1.3) 
 
0.134 
 
- 
 
- 
Type of housing 
Brick 
Iron Sheeting 
Mud 
Others 
 
35/51 (69) 
14/51 (27) 
0/51 (0) 
2/51 (4) 
 
97/103 (94) 
0/103 (0) 
2/103 (2) 
4/103 (4) 
 
Reference 
Undefined 
Undefined 
1.4 (0.2-7.9) 
 
<0.001 
 
NS 
 
NS 
≥2 Rooms for sleeping 28/50 (56) 84/101 (83) 3.9 (1.8-8.3) <0.001 4.9 (2.1-11.3) <0.001 
>2 people sleeping in a 
room 
Clinical presentation 
46/50 (92) 100/101 (99) 8.7 (0.9-80.0) 0.023 NS NS 
Symptoms <2 days prior 
to admission 
 
17/50 (34) 
 
51/102 (50) 
 
1.9 (1.0-3.9) 
 
0.062 
 
NS 
 
NS 
Antibiotics prescribed on 
admission 
 
45/50 (90) 
 
101/102 (98) 
 
5.6 (1.0-30.0) 
 
0.025 
 
12.5 (1.3-119.4) 
 
0.028 
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Difficulty breathing 43/50 (86) 90/103 (87) 0.9 (0.3-2.3)  0.812 - - 
Unable to drink or feed 13/50 (26) 34/103 (33) 0.7 (0.3-1.5) 0.378 - - 
Use of oxygen 43/50 (86) 83/103 (81) 0.7 (0.3-1.7) 0.402 - - 
Admission into ICU 0/50 (0) 0/103 (0) Undefined - - - 
Mechanical ventilation 0/50 (0) 19/103 (18) Undefined 0.001 NE NE 
Duration of 
hospitalization 
<2 days 
2-7 days 
>7 days 
 
4/51 (8) 
25/51 (49) 
22/51 (43) 
Median=5 
days,  
IQR(1-59) 
 
18/102 (18) 
62/102 (61) 
22/102 (21) 
Median=3 
days,  
IQR(0-26) 
 
4.5 (1.3-15.5) 
2.5 (1.2-5.3) 
Reference 
 
0.014 
 
 
0.013 
 
NS 
 
NS 
TB therapy started on 
admission 
 
3/50 (6) 
 
4/103 (4) 
 
0.6 (0.1-2.9) 
 
0.557 
 
- 
 
- 
HIV infection 17/30 (57) 30/66 (46) 0.6 (0.3-1.5) 0.308 - - 
Tuberculosis 2/50 (13) 2/103 (25) 0.5 (0.1-4.1) 0.482 - - 
       
Prematurity 1/50 (2) 0/102 (0) Undefined - - - 
Malnutrition (reported) 1/50 (2) 3/102 (3) 0.7 (0.1-6.6) 0.733 - - 
Malnutrition (weight for 
age) 
3/4 (75) 12/26 (46) 0.3 (0.03-3.1) 0.283 - - 
Chronic lung diseases 1/50 (2) 0/102 (0) Undefined - - - 
Asthma 0/50 (0) 0/102 (0) Undefined - - - 
Renal diseases 0/50 (0) 0/102 (0) Undefined - - - 
Heart diseases 0/50 (0) 0/102 (0) Undefined - - - 
Diabetes 0/50 (0) 0/102 (0) Undefined - - - 
Neurological diseases 1/50 (2) 1/102 (1) 0.5 (0.03-7.9) 0.604 - - 
Respiratory pathogens 
identified 
      
Influenza 4/50 (8) 4/90 (4) 0.5 (0.1-2.2) 0.385 - - 
Adenovirus 12/48 (25) 12/79 (15) 0.5 (0.2-1.3) 0.171 - - 
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Enterovirus 5/50 (10) 9/90 (10) 1.0 (0.3-3.2) 1.000 - - 
Rhinovirus 11/50 (22) 30/90 (33) 1.8 (0.8-3.9) 0.152 - - 
Respiratory syncytial 
virus 
8/50 (16) 5/90 (6) 0.3 (0.1-1.0) 0.047 NS NS 
Human 
metapneumovirus  
2/50 (4) 2/90 (2) 0.5 (0.1-4.0) 0.545 - - 
Parainfluenza virus 1 1/50 (2) 1/90 (1) 0.6 (0.03-9.0) 0.671 - - 
Parainfluenza virus 2 1/50 (2) 1/90 (1) 0.6 (0.03-9.0) 0.671 - - 
Parainfluenza virus 3 4/50 (8) 5/90 (6) 0.7 (0.2-2.6) 0.572 - - 
Parainfluenza virus 1,2 
or 3 
5/50 (10) 7/90 (8) 0.8 (0.2-92.5) 0.653 - - 
Any respiratory virus 33/50 (66) 55/90 (61) 0.8 (0.4-91.7) 0.565 - - 
More than 1 respiratory 
virus 
19/50 (38) 20/90 (22) 0.5 (0.2-1.0) 0.049 0.4 (0.1-0.9) 0.032 
Pneumococcal infection 
on lytA PCR 
 
1/16 (6) 
 
8/74 (11) 
 
0.5 (0.1-4.7) 
 
0.581 
 
- 
 
- 
Blood culture 36/51 (71) 11/103 (11) 0.05 (0.02-0.1) <0.001 NE NE 
Relevant bacterial 
infection on blood 
culture 
 
1/36 (3) 
 
0/11 (0) 
 
Undefined 
 
- 
 
- 
 
- 
 
 
 Variables statistically significant on univariate and multivariate logistic regression analysis 
presented in boldface. 
 Variables not statistically significant on univariate logistic regression (p>0.1) were omitted from 
the multivariable logistic regression model. 
 NE (Not evaluated): variables statistically significant on univariate analysis but omitted in the 
multivariate analysis. 
 NS (Not significant): variables not statistically significant on multivariate analysis (p≥0.05) 
 *IQR: Interquartile range 
  **The relevant invasive bacterial infections are Streptococcus pneumoniae, Haemophilus 
influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Neisseria meningitidis, Escherichia 
coli, Streptococcus agalactiae or group b streptococcus, Pseudomonas aerugenosa and 
Salmonella species 
  *** The organism that was relevant on bacterial culture in the child who died in the urban site is 
Klebsiella pneumoniae. 
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3.4.2 Univariate and multivariate analysis of factors associated with rural hospital 
site amongst children who died 
The variables found to be significantly associated with rural hospital site on univariate 
analysis using binary logistic regression at p<0.1 were black race, year, type of housing, 
2 or more rooms for sleeping, more than 2 people sleeping in a room, symptoms < 2 
days prior to admission, mechanical ventilation, duration of hospitalization, RSV, more 
than 1 respiratory virus and blood culture. (Table 4) 
On multivariate analysis, the factors independently associated with the rural site were 
>2 rooms for sleeping (OR 4.9, 95%CI 2.1-11.3), antibiotics prescribed on admission 
(OR 12.5, 95% CI 1.3-119.8) and individuals with more than one respiratory virus 
detected were less likely to be from the rural site (OR 0.4, 95%CI 0.1-0.9). (Table 4) 
 
 
 
3.5 Survival estimates in both rural and urban sites 
Amongst those that died, the median duration of reported onset of symptoms to 
admission was similar in both hospital sites, 2 days (IQR 0-7days) in the urban site and 
2 days (IQR 0-6 days) in the rural site, p=0.194. (Figure 2A) 
Figure 2A: Duration of symptoms (onset of symptoms to date of hospitalization) 
amongst those who died from SARI in urban and rural sites in South Africa, 2009 to 
2013. 
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Survival function in terms of symptom duration to death amongst those who died 
differed in both hospital sites (8 days (IQR 1-61) in urban and 5 days (IQR 1-28) in rural, 
p=0.009). The children in the rural site who died did so sooner after onset of symptoms 
than urban children. (Figure 2B) 
Figure 2B: Duration of symptoms to death (onset of symptoms to date of death) 
amongst those who died from SARI in urban and rural sites in South Africa, 2009 to 
2013.   
 
Survival function in terms of duration of hospitalization to death amongst those that died 
differed in urban and rural sites, (5 days (IQR 1-59) in urban and 3 days (IQR 1-27) in 
rural, p=0.0127). The rural children who died did so sooner after hospitalization 
compared with urban children. (Figure 2C) 
 
Figure 2C: Duration of 
hospitalization to death 
(date of hospitalization to 
date of death) amongst 
those who died from 
SARI in urban and rural 
sites in South Africa, 
2009 to 2013. 
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Although time from onset of symptoms to admission was the same in both sites 
(p=0.194), time from onset of symptoms to death differed (p=0.009) in both sites which 
supports our finding that duration of hospitalization to death differed at both sites 
(p=0.0127). 
 
3.6 HIV-infected children and HAART  
HIV prevalence amongst hospitalized SARI cases decreased over the study period at 
both sites; however the prevalence was consistently higher at the rural site compared to 
the urban site. Similarly the percentage of HIV positive children on HAART increased 
over the study period in the rural site and was consistently higher in the urban site 
initially. However, by 2013 the percentage of children on HAART was similar between 
the sites. (Table 5a) 
Table 5a: Percentage of children that are HIV-infected and those receiving HAART   
by year amongst children <5 years hospitalized with SARI in urban and rural 
hospital sites, South Africa, 2009-2012. 
  HIV-infected  HIV-infected children on HAART 
Year Urban site 
N=3811 
n/N (%) 
Rural site 
N=1486 
n/N (%) 
P value Urban site 
N=257 
n/N (%) 
Rural site 
N=233 
n/N (%) 
P value 
2009 102/655 (16) 53/166 (32) <0.001 34/78 (44) 5/26 (19) 0.637 
2010 62/503 (12) 73/262 (28)  16/37 (43) 9/28 (32)  
2011 37/513 (7) 35/220 (16)  7/23 (30) 7/13 (54)  
2012 44/559 (8) 46/259 (18)  13/26 (50) 13/23 (57)  
2013 12/263 (5) 26/219 (12)  5/8 (63) 10/18 (56)  
Overall 257/2493 (10) 233/1126 (21)  75/172 (44) 44/108 (41)  
Missing 
Data 
1318 360  85 125  
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On sensitivity analysis, assuming that all the children with missing data on HIV status 
were HIV-uninfected, the prevalence of HIV amongst hospitalized SARI cases also 
decreased over the study period at both sites and was consistently higher at the rural 
site compared to the urban site. (Table 5b) 
 
Table 5b: Percentage of children HIV-infected by year compared with sensitivity 
analysis (assuming all those with missing data were HIV-uninfected) amongst 
children <5 years hospitalized with SARI in urban and rural hospital sites, South 
Africa, 2009-2012. 
  HIV-infected HIV-infected (sensitivity analysis) 
Year Urban site 
N=2493 
n/N (%) 
Rural site 
N=1126 
n/N (%) 
Urban site 
N=3811 
n/N (%) 
Rural site    
N=1486 
n/N (%) 
2009 102/655 (16) 53/166 (32) 102/1031 (10) 53/330 (16) 
2010 62/503 (12) 73/262 (28) 62/791 (8) 73/303 (24) 
2011 37/513 (7) 35/220 (16) 37/795 (5) 35/252 (14) 
2012 44/559 (8) 46/259 (18) 44/793 (6) 46/306 (15) 
2013 12/263 (5) 26/219 (12) 12/401 (3) 26/295 (9) 
Overall 257/2493 (10) 233/1126 (21) 257/3811 (7) 233/1486 (16) 
 
 
Only 26% (129/490) of HIV-infected children had available CD4+ T-lymphocyte data, of 
whom 75% (83/110) in urban and 47% (9/19) in rural site had severe 
immunosuppression. Ninety percent (18/20) in urban and 10% (2/20) in rural of those 
with available CD4+ T-lymphocyte data reported receiving HAART. (Table 5c) 
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Table 5c: Percentage of children with severe immunosuppression by year 
amongst children <5 years with CD4 count hospitalized with SARI in urban and 
rural hospital sites, South Africa, 2009-2013. 
 Low CD4 count 
Year Urban site N=110 
n/N (%) 
Rural site N=19 
n/N (%) 
P value 
2009 31/40 (78) 1/1 (100) 0.162 
2010 20/26 (77) 2/4 (50)  
2011 9/15 (60) 0/2 (0)  
2012 16/20 (80) 4/7 (57)  
2013 7/9 (78) 2/5 (40)  
Overall 83/110 (75) 9/19 (47)  
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                                                        CHAPTER 4 
4.0 DISCUSSION 
4.1 Overview of study findings 
In this study, we described the demographic characteristics, clinical presentation and 
respiratory pathogens of children < 5 years of age hospitalized with SARI from rural and 
urban sites in South Africa and also identified the risk factors for mortality amongst 
these children in these 2 sites separately.  
The CFP was 1.3% in the urban site and 6.9% in the rural site. HIV infection was 
associated with death in the urban site. In the rural site HIV infection, children aged less 
than 1 year, malnutrition, pneumococcal infection on lytA PCR were associated with 
increased mortality while individuals with respiratory virus detected were less likely to 
die. This study serves as an important benchmark in addressing areas in which to 
intervene for reducing mortality in children less than 5 years of age in different parts of 
South Africa. 
 
4.2 Case fatality proportion 
Our result shows that SARI causes substantially higher mortality in the rural area (6.9%) 
than in the urban site (1.3%), this is similar to findings recorded in China and 
Bangladesh from their national demographic surveillance system which recorded 
mortality that is 4.9 and 1.4 fold higher respectively in the rural area compared to urban 
area.(75, 76) However 7% mortality from the rural site in this study is similar to but 
slightly lower than 9% mortality that was reported from rural Thailand.(77) A case series 
study from 8 countries in Africa reported 2.8% (country range 0.1-5.3%) SARI deaths 
overall which is very similar to the overall mortality in this study (2.9%), this finding is 
however much lower than the mortality rate from our rural site.(32) The higher CPF 
recorded in the rural hospital site could possibly be that rural children present with more 
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severe form of illness, it could also be that the quality of in-hospital care might not be as 
good as in the urban hospital and IMCI guidelines not strictly enforced. Another 
possibility is data issues e.g. bias. Some children could have been too sick to be 
enrolled and died soon after presentation leading to underestimation of mortality which 
could have occurred in either site. Although the highest proportion of patients in the 
urban site required oxygen therapy compared to the rural site, possible reason could be 
that oxygen was more readily available and not necessarily because they had a more 
severe presentation. Moreover, CHBAH is a highly specialized hospital with 12 neonatal 
ICU beds and paediatric subspecialties such as oncology, renal, cardiac, haematology 
and neurology units. (78) CHBAH strives to achieve the highest level of patient care 
based on sound scientific principles and administered with empathy and insight: (69) 
therefore the quality of in-hospital care may be able to mitigate against the risk posed by 
other factors.  
It is therefore important to analyze mortality in rural and urban settings separately in 
order to define the problems facing each site and also the specific intervention that will 
be required by each site. 
4.3.1 HIV as a risk factor for mortality 
In both sites HIV was a risk factor for death. Almost 21% of children admitted with SARI 
in the rural area were HIV-infected while in the urban area over 10% were HIV-infected. 
HIV-infected individuals had 11 times greater mortality rate than HIV-uninfected children 
in the urban site (CFR for HIV-infected children was 6.6% and for HIV-uninfected 
children 0.6%) while in the rural site HIV-infected individuals had 3 times greater 
mortality rate than HIV-uninfected children (CFR for HIV-infected children was 12.9% 
and for HIV-uninfected children 4.2%), moreover there was a real difference in the OR 
of death in HIV-infected children by site [urban 12.1 (5.8-25.2) and rural 3.5 (2.1-5.58)]. 
This finding from our urban site was consistent with other studies carried out in South 
Africa which estimated approximately 10 times elevated mortality risk in HIV-infected 
children and also globally.(30, 79) Amongst those that died in the urban site 57.7% were 
HIV-infected while in the rural area 45.5% were HIV-infected. There have been studies 
showing that reduction in SARI is associated with availability of HAART but despite this, 
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high incidence of SARI is still reported in HIV-infected children on HAART, (80-83) 
hence the impact of HIV as an underlying risk factor for SARI mortality despite the 
widespread availability of HAART cannot be over emphasized. Of the 13.5% HIV 
infected children overall, 67% and 27% of these children had data on HIV treatment and 
CD4 count respectively. Only about a quarter of HIV-infected children were on treatment 
with HAART while even fewer had available CD4+ T-lymphocyte data, of whom majority 
had severe immunosuppression.(84) Stratifying the HIV prevalence by year, the 
prevalence was seen to be reducing at both sites but the prevalence at the rural site 
was consistently double than that of the urban site. (Table 5a).This could be driven by 
the fact that underlying HIV prevalence differ in both communities, according to Shisana 
et al in the South African National HIV prevalence, incidence and behaviour survey of 
2012, the HIV prevalence amongst children < 14 years in 2008 was 2.2% and 3.8% in 
Gauteng and Mpumalanga province respectively while in 2012 it was 2.1% and 1.7% in 
Gauteng and Mpumalanga province respectively.(35) In infants the HIV prevalence was 
higher in Mpumalanga province (3.0%) compared to 1.1% in Gauteng province.(85) 
From the 2012 National antenatal sentinel HIV & Herpes simplex type-2 prevalence 
survey in South Africa, the HIV prevalence amongst pregnant women was consistently 
higher in Mpumalanga province (rural) [2010 (35%), 2011(37%), 2012 (36%)] compared 
to Gauteng province (urban) [2010 (30%), 2011(29%), 2012 (30%)].(86) MTCT of HIV 
infection could also contribute to this, the MTCT in 2012 was much higher in 
Mpumalanga province 5.7% (CI 4.1-7.3) while in our urban site (Gauteng) it was 2.5% 
(CI 1.5-3.6).(85) However, the magnitude of the difference in community prevalence 
seems unlikely to fully explain why the prevalence of HIV was consistently doubled in 
the rural site compared to the urban site. 
Looking at the percentage of children on HAART by year, an increased trend was 
observed with children on HAART from 2009-2012 in the rural site (Table 5a). In this 
study data on HAART was not analyzed in our multivariate model because of missing 
data. On sensitivity analysis, assuming that all the children not tested for HIV were HIV-
uninfected the trend towards a reduction in prevalence at both sites except in 2012 and 
doubled prevalence in the rural site remained in all years (Table 5b). 
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In the rural site several factors were associated with mortality apart from HIV including; 
age, malnutrition, pneumococcal infection on lytA PCR and identification of any 
respiratory virus. The difference in risk factors between urban and rural sites could be 
due to lower power to detect a significant difference for some factors in the urban area 
because of the fewer deaths recorded. Alternatively, it is possible that perhaps in the 
urban site patients have earlier access to high quality care and antibiotics even before 
admission and so this reduces impact of some other factors leaving only HIV as a risk 
factor for death. 
4.3.2 Age as a risk factor for mortality 
We found that age is an important risk factor for SARI-mortality in the rural site. Children 
aged < 12 months have a higher CFP (9.4%) and also a higher risk of death (OR 3.5, 
95% CI 2.0-6.1) compared to children aged 1-4 years with CFP of 3.4% in the rural site. 
This is similar to studies from Africa and the USA where mortality is higher in children < 
1 year compared to older children < 5 years of age.(41, 55, 87, 88) Sonego et al in a 
systematic review and meta-analysis of observational studies from low and middle 
income countries also reported age below 2 months as a risk factor for mortality in 
children with ALRTI (OR 5.22, 1.70-16.0).(31) This could be due to lower immunity 
experienced by the younger age group (new born and infants) making them more 
susceptible to severe forms of infections and hence increased mortality. (89) 
 
4.3.3 Malnutrition as a risk factor for mortality 
Malnutrition was significantly associated with mortality in the rural area (OR=12.8, 95% 
CI 1.2-134.6). This is similar to estimates from a systemic review on pneumonia in 
severely malnourished children in developing countries (OR ranged from 2.5-15.1 and 
relative risk (RR) ranged from 2.9-121.2) and also corroborates the study by Caulfield et 
al that reported malnutrition as a risk factor for mortality in children with pneumonia 
(OR=8.1, 95%CI 4.4-15.0). (42, 90) Furthermore in a review of findings from cohort and 
case-control studies by Rice et al, a strong and consistent relationship was observed 
between malnutrition and increased risk of death from ARI.(44) These suggest that 
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malnutrition in children contribute significantly towards the burden of SARI. A child's 
immune system may be weakened by malnutrition or undernourishment, especially in 
infants who are not exclusively breastfed.(91)  
 
4.3.4 Detection of respiratory virus as being associated with lower mortality 
Any respiratory virus was significantly protective against mortality in this study in the 
rural site. The CFR in those without any respiratory virus was twice those with any 
respiratory virus. This could be that amongst children hospitalized with SARI who do not 
die, viral etiologies are more implicated compared to bacterial etiologies, however 
amongst children who die bacterial etiologies are more implicated as these are often 
more severe and more likely to result in death.(92) This could potentially be more 
marked in rural setting where access to antibiotics could be delayed, although we did 
not have data on timing of antibiotic administration to assess this and time from 
symptom onset to death was shorter in the rural than the urban site. 
This is similar to what McMorrow reported with influenza-associated SARI deaths in 
Sub-Saharan Africa (CFP was 1.8% (57/3091) for influenza positive cases, compared 
with 2.9% (1016/34 623) for influenza virus-negative cases and also support study from 
South Africa, using the same dataset, that reported that children with RSV-associated 
ALRTI are less likely to die compared to those testing RSV-negative.(32, 51) Nair et al 
in a systematic review concluded that RSV is a major cause of mortality in children 
because of its huge burden, however case fatality ratio (CFR) for RSV in developing 
countries is 2.1% in children with ALRTI which is higher compared to CFR for RSV in 
children with ALRTI in industrialized countries. (41) 
 
4.3.5 Pneumococcal infection as a risk factor for mortality 
Overall, 52.9% of the children were tested for pneumococcal infection on lytA PCR; 
pneumococcal infection was significantly associated with mortality in the rural site in this 
study. Those who tested positive for pneumococcal infection were more likely to die 
compared to those who tested negative for pneumococcus. This study is consistent with 
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studies from South Africa, India, global estimates and systemic reviews which reported 
pneumococcal infection being associated with death in children with SARI, (6, 52-54) 
Cohen et al reported pneumococcal co-infection as a risk factor for death amongst 
children with viral associated ALRTI (OR: 2.4, 95% CI 1.1-5.6) using the same data.(6) 
In our study vaccination with 2 or more doses of PCV was significantly higher in the 
urban site compared to the rural site. Despite advances in preventing SARI caused by 
S. pneumoniae with the introduction of pneumococcal conjugate vaccine, 
pneumococcus is still implicated in some of SARI deaths. Diagnostic tests for 
pneumococcal pneumonia have low sensitivity and so the contribution of 
pneumococcus is likely greater than the 6% of individuals testing lytA positive in our 
study.(93) 
Delay in presentation to the hospital as a possibility for increased mortality in the rural 
site was not supported by data because rural patients reported shorter interval between 
symptom onset and hospitalization and death. Other factors like underlying medical 
conditions and quality of care that’s delivered at each site could affect the mortality rate 
in each site. 
 
4.3.6 Variables not significantly associated with mortality 
This study does not show sex as a significant risk factor for death in either study sites, 
which also support results from one study, (47) but there are studies which have shown 
the female sex having increased odds of dying. (31, 46)  Some studies have also 
reported disease duration of more than 21 days from onset of illness to presentation as 
a risk factor for mortality,(46) however we could not explain this because we only 
included patients with symptoms less than 7 days in our study. 
The CFP was low in 2009 and peaked in 2010 at both sites with a gradual decline in the 
CFP trend from 2011-2013. This could be attributed to improved health care system in 
the last few years, PCV introduction, widespread availability of HAART and prevention 
PMTCT. 
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4.4 Residual confounding 
Data on some variables that could be possible confounders like indoor air pollution, 
socio-economic status, type of feeding, were not collected, therefore there could still be 
residual confounders which we did not measure and could not include. Result of 
pneumococcal infection was used in the multivariate analysis instead of bacterial culture 
result to prevent multicollinearity and we had more children that were tested for 
pneumococcal infection on lytA PCR than those that had blood culture especially in the 
rural site where very few of the children had a blood culture.  
4.5 Study strengths 
The strength of this study is the use of active surveillance data on SARI. The data 
include large number of cases over 5 year period which powered the study to be able to 
determine the risk factors for mortality in children with SARI. Data from the urban and 
rural sites were systematically collected over a long and similar period with a consistent 
protocol and methodology making the data comparable and allowing comparison 
between the urban and rural sites. 
4.6 Study limitations 
There are several limitations in this study. This study used cases from specific 
surveillance sites which could have introduced selection bias and therefore the results 
might not be generalizable to other sites. This study population includes hospitalized 
children alone, some children could have died at home; others may have died soon 
after presentation and children who die are less likely to be enrolled as they may be too 
sick or die quickly before enrolment which might lead to underestimation of mortality. 
Malnutrition was significantly associated with mortality in the rural site. Initially in the 
study malnutrition was collected from clinical records or clinician reported so there could 
be the possibility of information bias. More robust data including weight and height was 
collected from 2012, but these data were not included in multivariate models due to 
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large amount of missing data. Other factors outside the hospital like use of coal/wood or 
natural gas for cooking, indoor air pollution, type of feeding, low socio-economic status 
would have been considered but these were not in the original data collected.  
Another limitation is missing information. Systematic testing for bacterial agents was 
limited to Streptococcus pneumoniae which had lots of missing data and for viruses (10 
viruses were tested). Blood culture was only done on a minority of cases, some blood 
culture data were available, but only few from rural site. Tachypnoea variable seems to 
have been systematically incorrectly recorded at the rural site; hence we did not include 
it in our analysis. HIV data were incomplete and data on CD4 count and ARV use were 
very scanty, also data on HIV exposure was not collected. 
 
4.7 CONCLUSION AND RECOMMENDATION 
In conclusion, we have demonstrated a higher SARI mortality in the rural site than in the 
urban site. This was observed among both HIV-infected and HIV-uninfected children. 
We have also demonstrated HIV as a significant risk factor for SARI mortality in both 
urban and rural South African settings. There was a higher CFP amongst children <1 
year at both sites compared to children aged 1-4 years and we also found age <1 year 
vs. 1-4 years as a significant risk factor for SARI death in the rural site. Other risk 
factors significantly associated with death in the rural sites were reported malnutrition, 
absence of any respiratory virus detected and pneumococcal infection on lytA PCR. HIV 
still plays a huge role in SARI mortality in children less than 5 years old even in the era 
of widespread availability of PMTCT and HAART as 49% of those that died overall were 
HIV positive.  
 
Recommendations 
The results presented in this study suggest that more focus still needs to be put on HIV 
prevention and treatment. Increase in campaign on HIV prevention by providing more 
information and education on HIV prevention, further reduction in MTCT by advocating 
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for pregnant women to present to the hospital as early as possible for antenatal care, 
voluntary counseling and testing, prophylactic anti-retroviral therapy to reduce 
transmission, ensuring safe delivery practices, increased counseling and improved 
support for safer infant feeding practices. These preventive methods need more 
attention in order to further reduce the burden of HIV in the communities. 
Improving adherence to IMCI guidelines in South Africa which involves case 
management skills of health care workers, improving overall health systems, improving 
family and community health practices and effective pneumonia management has been 
found to play a major role in reducing the burden of SARI,(94) although there may be 
differences in how this is applied between the rural and urban areas. Introduction of the 
IMCI strategy has also helped to develop and update national policies in the 
management of sick children. (95) 
Assisting those that are poor and do not have easy accessibility to health care 
especially those in the rural site even though health care is free for children < 5 years 
old. Making more clinics available in the rural sites and closer to their homes and 
bringing the hospitals closer to the communities can improve accessibility to health 
care. Access to effective health care for children can go a long way in improving health 
outcomes.  
The malnutrition challenge is multifactorial; some factors like promotion of 
breastfeeding, food-aid programs and supplemental programs with iron and vitamin A, 
maternal education and alleviation of poverty could be addressed.  
Efforts to prevent and treat HIV infections in children and reduce malnutrition may also 
reduce SARI deaths. 
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Datecompleted, 
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-: I 
.'
(DD/MM/YYYY)
SARI Study lD: TSAP Study lD:
ru#ts.'F'sr dd*xd*ie
#ospifol **/y r, psf,*sa
r*-**r*#*d i* FS$P {fii$y.
Patient Hospitalised at: CHBH L: Selby if Mapulaneng - -. Matikwana l---1
Edendalel. Klerksdorp- Tshepong
Note: surveillonce oificer to review criteria lor all case definitions belore making o decision about the case definition/s me
SARI* tl SRI** (severe respiratory illness not SARI) X Febrile illness*** (enrolled on TSAP) tl
*SARI with durotion ol symptoms < 7 doys,
*+ SARI with durotion of symptoms > 7 doys, ,AN/rB or TB (for Edendale ond Klerksdorp-Tshepong Hospitdl Complex only).
***lf pdtient co-enrolled in the TSAP study (for Edendole Hospinl only).
NB: For Edendale ond Klerksdorp-Tshepong Hospital Complex only
Enrolled in shedding study Yes 1"-,j No fI
t. Date of birth (DoB): :"11*iil-1i-;ll^ illi-l= lf DoB unknown, please enter ase:-Years i*J vo4qfi oavs l- i
2. Gender: n Female i-iMale
3. Race: Asian/tndian Tl Black ll coloured lf white l-'l other :l (specifv)
4. What is your house made of: Bricks i-l lron sheeting l--"i ruud I j other i J (Specify)
5. Number of rooms used for sleeping? 5.1 Number of people living in the house?
6. What is the interviewee's relationship to the participant? Self f] Parent/Caregiver il Other il (Specifu)
7. Date of admissionl l*l 1-l rl-l l*l $l Tl T-l Tl
Admission diagnosis:
(Tick all that apply)
Neonatal Sepsis f,
TB il Bronchitis
other fl (specify)-
Bronchiolitis n Bronchopneumonia/Pneumonia/Lower Respiratory Tract lnfection I
il Diarrhoea il Febrile seizures I Meningitis I Sepsis (not neonatal) [
8.
e. Date of onset of symptoms: i- lr--lr'*",,]rni*lT-li-'.l
9.1 Durationofsymptoms: 0-7days I 8-14days f, >14days
Note: Complete the signs ond symptoms ot the time ol odmission, some o! the signs or symptoms may hove resolved by the time you interview
the potient. This lnlormotion should be avoilable in the patlent records.
L0. Maximum recorded temperature within 24hours of admission 
-.-C" 
{##'#C')
Note: Record the moximum temperdturc recorded in the clinicol notes or o tempetoture taken by the surueillonce officer within 24 hours of
odmission if no temperoture in the file.
1 1. Date of maxi mu m tem pe ratu re record ed : I-: L]li,--] ffi lj ;-,1 I--- ;""-] Temperature not recorded f
12. Historyof fever? ves f-l t'lo i I unf l-*l tf yes, date of fever onset: ::il/|l]ruij':fli:]-
13, Respiratorv Rate: breaths per minute Not recorded L]
14. oxygen saturation (room air): % Date of 02 Saturation: i--1lll1;i,:r---1li--ii ..jl-,i-]
Recorded on file il Measure by Surveillance Officer within 24h of admission i-
15. Patient leneth (if not recorded, surveillance officer to measure): cm Percentile {if oatient < 5 vears) Unk
15.1 Patientweight(if notrecorded,surveillanceofficertomgasure):-.-kg Perceltile(if patlent<5years)- Unk I
15.2 Mid upper arm circumference (MUAC) (for patients < 5Yelfq9&8-e--S!!y-l cm
Case lnvestieation [orm (ClF]
Centre for Respiratory Diseases and Meningitis (CRDM)
TEL: 011 386 6410 or 011 385 5434
FAx: 086 723 3569
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16. Blood pressure on dav of admission: I Not recorded l]l
17. Mental status of the patient (based on AVPU), within 24 hours of admission
Alert f] Disorientated f Stuporous f] Comatose u Sedated i: Unknown I j(responds to verbal commands) (responds to painful stimuli)
Note: ff patient is olert report 75/75.
18. Glasgow Coma Score (GCS) /15 GCS from medical records: yes I No I
GCS Unk T*l (if patient not alert and GCS not recorded on medical records)
Note: Complete for potients 2 72 yeors, il potient < 72 yeorc skip to Q 20,
19. Patient oriented to:
Person: yes l-l no !I Unk f,l Place: Yes il No tr Unk tl time: Yes fl ruo fl Unk ff
Note: Complete the table below for children < 5 yedrs, if potient 2 5 years skip to Q 27.
20. Were any of the following signs and symptoms present?
Cough N Difficulty breathing N Chest in drawing
I retraction) N
Stridor in a calm child N
Tachypnoea/respi ratory
distress (2mnth-lyr RR>50, 1-5
RR>40)
N
Diarrhoea
(>3 loose stools per day) N
Unable to drink or breast feed N Vomits everything N Convulsions N
Lethargy N Unconsciousness N Any vomiting N
Wheezing N
Note: Complete the table below lor pdtients > 5 yeors, il patient < 5 yearc skip to Q 22.
21. Were any of the following signs and symptoms present?
Sore throat N Cough N Chest pain N
Shortness of breath/difficulty
breathine N
Diarrhoea
(>3 loose stools per dav) N Wheezing N
Note: Complete the tahle below for oll patients.
22. Were any of the following signs and symptoms present?
Chronic cough for 2 weeks or
more
N
Fever for more than 2 weeks
{14 davs) N
Cough up blood
(Hemoptvsis) N
Loss of appetite N Nisht sweats N Loss of weight N
Painless enlarged lymph glands N
History of close contact with a
person with recently active TB
(diagnosis < 12 months ago)
N
lf yes, is the patient staying in the
same house with the TB contact
N
Note: Complete the lollowing questions lor pdtients 2 78 yedrs, if potient < 78 years skip to Q 26'
23. Do vou drink alcohol? Yes Ll No il lf yes, how m?!y q!l!!Iglry99!1
24. Do vou currentlv smoke? Yes l] No [f lf yes, how many cigarettes dq yq! qrnelg !g!4?-
24,r tf no, have you smoked in the past? Yes l--j No L,:l tf yes, date stopped smoking: i 
--lll,'l'.-]lLlli:jl=:';i ,:l
25. Do you currently or have you ever worked in a mine before? Yes ff No il Unk il
Note: tI no or unknown, skip to Q 26)
25.1 lf yes, date started working in the mine: l-l]li:-j[ll-]ililil 
--- -lel*lqeyf1il
25.2 tf working in a mine or worked in a mine before, when did you stop working in the mine? l.*-1i-:il-.i- .]li*iil[:i-] ongoing l-i
Date Unknown . ""
;, -.r,**t 
", 
-r*, in mine before, what type of mine/s? (tl
SARI Surveillance Programme
Case lnvestigation Form (ClF)
Version: 18Dec 2012
Page 2 of 5
78
Gold i"--l coal i--r Platinum |] Rsbestos i- -1 other I I (specify)
26. Do you have any underlying illness or condition at the moment? Yes I No f]
Note: Check potient's notes for details if necessory. lf no skip to Q 27
Asthma N Other chronic lung disease N CVA/SIroke N
Cirrhosis/Liver failure N Chronic renal failure N Heart failure N
Valvular heart disease N Coronary artery disease (except H/T) N Pregnancy N
Organ transplant N Any immunosuppressive 
therapy,
cortisone, chemotherapy, radiation therapy N Sickle 
cell N
Splenectomy N Diabetes N Burns N
lmmunoglobulin deficiency N Autoimmune disease, SLE N
Kwashiorkor/
Marasmus N
Nephrotic syndrome N Spinal cord iniurv N Seizure disorder N
Prematurity N Obesity / BMI >=30 N COPD/Emphysema N
Malienancv/Cancer N lf yes, specify:
Other N lf ves, specifv:
Does the patient live in an
institution/care facility N lf yes, name of institution:
27. Has the patient been admitted to hospital in the last l2months? (prior to this admission) Yes fi fto ff Unk fi
Note: lf no or unknown, skip to Q 28.
Date Unk
27.2 Wasthe patient admitted more than once in the past year? Yes f No il Unk u lf yes, how many times?
Note: Complete Ior potients < 5 yeors, iI potient > 5 yeors skip to Q 29.
28. HIV result during pregnancy (mother of patient): Yes f] No ff
Note: lf no or unk skip to Q 29
Unk LI
28.1 lf ves. what was the result? Positive l*l Negative n
28.2 What was the source of the results? RTHC Tl Laboratory report il] Medical records I Verbal I qilqI:lpEg,fy
28.3 WasthechildexposedtoHlV(yesifthemothertestedHlVpSsflifduringpregnancy) nk I N/e il
29. Has the patient been tested for HIV prior to this admission? Yes f No f Unk I
Note: lf no or unknoin skip to Q 30
29.1 lf yes, what was the result? Positive
Note: ff negotive or unknown skip to Q 30
i: Negative u Unk u
29.2 CurrentlyonART? yes l"l ruo ij unknown f] tf yes, date of initiation of Anr: fifJ/|*-]i::lIl;J:il
29.3 Bactrim (contrimoxazole/trimethoprim) prophylaxistaken currently? Yes f No il Unk [f
Note: ff no or unknown skip to Q29.5
29.4 lfves,howlonghavevoutaken Bactrim?-Years-Months Weeks-Days
29.5 What is the patient's clinical HIV stage according to WHO criteria (refer to WHO clinical staging information and HIV staging tick box
document)
1[:] 2n 3il 4[
30. Have you ever taken TB prophylaxis? Yes l*-j t'lo il unr< tf yes, date TB prophylaxis initiated: l,..,"Jl.- lllf i" lli -.lllf*]il
Note: ff no or unknown skip to Q 37
30.1 Are you still taking TB prophylaxis?
Note: f yes skip to Q 32
Yes il No rs Unk il: tf no, date rB prophylaxis stopped: i-ll-jil--]t]l;:i_]il]l:
31. TB treatment in the tast 12 months? ves I I ruo L-j unr 1""^l tf yes, date TB treatment initiated: Ijilit]LjlllIj;:t:
Note: ll no or unknown skip to Q 32
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31.1 Are you still taking TB treatment? ves I uo i-: unf< i-J lf no, date TB treatment stopped: Lll:.j/L,li:/l
Note: Ask patients ond check medical records lor PCP diognosis dnd/or treotment
32. Have you ever been diagnosed with PCP before this admission? (check from medical records) Yes I No [f Unk f
Note: U no or unknown skip to Q 33
32.1 tf yes, date last treatment started: ill-]ll;l-]ll ji:llil qlfu-VL:!-l*l-
32.2 tf yes, date last treatment stopped: l-ll-l{-, t|.lil-llll--li-j oate unk l-"-l .olc-gils i--i
32.3 lf ves. treatment started with steroid therapy? Yes n ruo [f Unk f]
33. Hasthepatientbeenprescribedandtakenantibioticsinthe24hoursbeforethisadmission? Yes I No I Unk t
Note: f no or unknown skip to Q 34
33.1 lf yes, what is the name of the antibiotic? 7. 2. 3,
AMO Amoxicillin; AMP Ampicillin; AUG Augmentin; CEF Cefuroxime, CIP Ciprofloxacin; CLI Clindamycin; CTX Ceftriaxone; DOX Doxycycline; ERY
Erwhromvcin, PEN Penicillin, TMX/SMX Contrimoxazole, VAN Vancomycin. lf other, specify 
-
34, Voccination history. Complete Ior pdtients < 5 yedrs, il patient 2 5 yeors skip to Q 35
34.1 ls the person being interviewed the primary caregiver of the child? Yes I No I
Note: ll no skip to Q 34.3
34.2 lf yes, has the child ever been vaccinated?
Note: Excluding the voccines given ot birth
Yes il No u Unk l:
34.3 Was the Road to Health Card seen? Yes il No il 34.4 Was a copy of the Road to Health Card made? Yes f] No il
Note: lf no skip to Q 35
34.5 lf copy was not made, state reason: Mother refused i] Other [ (specify)
t Road to Heolth Cord seen, pleose copy the lollowing inlormation from the card:
34.6 What is patients'gestational age: Term f] Pre-term f Not recorded on Road to Health Card f]
lf pre-term, record gestational age: weeks
34.7 lf Road to Health Card seen, please complete the details on the following vaccines for all children < 5 years old
Note: Tick no for voccines that are not yet due occording to the schedule. At 78 months il only the DTP wos given tick DTP only ond N/A lor the
combined DTP/HIB, if o combined DTP/H\B wos given tick yes under combined ond N/A under DTP only
Vaccine Dose due Given Date siven
BCG Birth N ililiililJrllL:ul:
DTP
+
HIB vaccine
Dose 1 (6 weeks) N t--tl trt Il j;L:uilm
Dose 2 (10 weeks) N t:ilrililrtilnn
Dose 3 (14 weeks) N i't!* lrl il-lri::1ilili:
Dose 4 (18 months) N N/A l*l fl rf-r f-lri-l il l-l il
DTP only (tick N/A if DTP+HIB) Dose 4 (18 months) N IN/A r-:[- ]ii][,];il;:ilI]
S.pneumoniae conjugate
vaccine (PCV7713/Prevenar)
Dose L (6 weeks) Y
Batch N" unk i"l
N triliflilrt]ililn
Dose 2 (14 weeks) Y
Batch N'- Unk i-l
N Liillrtil-:Iili:illi-l
Dose 3 (9 months) Y
Batch N" Unk !,,]
N aJtr,JltUilnn
Catch up Y
Batch N" Unk l]
N i*lt..lI*lilri:n[il
Measles
Dose 1 (9 months) N i-lllr[-][-irtli:ili:
Dose 2 (18 months) N t*I td-]_irill:il[
SARI Surveillance Programme
Case lnvestigation Form (ClF)
Version:18Dec 2012
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-Hepatitis B
Dose 1. (6 weeks) N l-lI lrl- lLlrl]LlL lt:
Dose 2 (10 weeks) N l-lllrl-lTl;TlT:iln
Dose 3 (L4 weeks) N Il---lLJ[rri:IlilL*]
Rotavirus
Dose 1 (6 weeks) N i*ll*lrl-lTlrilr^'tl:f-l
Dose 2 (14 weeks) N ill lrl ll lrUilLltf
Note: Complete for potients 2 5 yeors, if patient < 5 years skip to Q 35
35. Did the patient receive pneumococcal polvsaccharide vaccine?
Vaccine Dose given Date siven
Date unknown [.]
Pneumococcal Vaccine (Pneumovax) N UNK t]Irl ]Url,ftllll]
36. Did the patient receive an influenza vaccine in the past L2 months (For all patients)
Vaccine Dose qiven Date given
lnfluenza vaccine
Dose 1 N UNK i il liillI );:l,li::il Date unknown f
Dose 2 N UNK UilrilUrUi:mill Date unknown f]
QC Performed by: lnitials: I 
-ji il -"1 oate: ilLfll fillnLll:tl
SARI Surveillance Programme
Case lnvestigation Form (ClF)
Version: 18Dec 2012
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Severe Acute Respiratorv Illness (SARIl Surveillance
Hospital Results Form (HRF)
Centre for Respiratory Diseases and MeninBitis (CRDM)
TEL:011 385 6410 or 011 386 6434
FAX:086 723 3569
SARI Surveillance Programme
Hospital Results Form {HRF}
Vpr(ion! 1 I December 2O12 Final
l:ii
;TSAP Studv lDi
i
il
ilil
i '-
SO lnitials: I I l_l i--_j
i-- ri"" i .i--"!i' ', ,i :,- 'l; - ,;''- I SARI StUdy lDDatecompleted:: 
_, _ ' ,. 
.-','_i-t 
:
(DD/MM/YYYY)
iVcls; #*r ffder?d$fe
-^ ^*-- tJ*J ;,-UU^tr'J'UTIgL' IiI
t* A * .-t:,^'",
Please record these results trom the laboratory if they are available.
Note: Only results lrom this admission except for Q 4, 5 and I where the most recent available resuft should be entered and Q 7 where
results before admission must be recorded.
Test Date of test Result
]..CRPonadmissionoone[-ltltotdoneillr]I;l*li-lli*]l-ll-li-l-mE/|
2.ESRonadmissionoone|-^,Notdonei""ji']l]l:ll-""]lll;:"::.,-mm/Hr
3. Urea on admission Done i.-- ttot done l*j l--ll-i,ti" l[]/il[;:* 
-mmol/l
:,*""- :
-r'L*--J-- I
No l*l Note: Enter ddte oI most recent
result availoble
Reactive l-; Non reactive IilYes4. Documented HIVAntibody Result (ELISA or
rapid) Note: Enter most recent result ovailable
-*--''i'*,']
---!,* i- ----.' ji il .-"
No l*J Note: Enter date of most recent
result ovoiloble
t:Yes5. Documented HIV PCRResult Positive i.-.1 Negative llNote: Enter most recent result availoble
6. Based on all the information available to you, what is the current HIV status of the patient Positive fl Negative f, Pending !
Unknown l*l
6.L lf current HIV status unknown, why was the patient not tested? Refused consent l] Patient died I No guardian ff
Other i-l specifv
6.2 What was the source of the results? RTHC [: Laboratory report f] Medical records f] Verbal ff other f, Specify
6.3 if patient < 5 years, was the child exposed to HIV : N/A il Yes il trto il Unk il
7. CD4 count on
admission
Done ll Not done iJ r-1r -.:i-: i''_:f-'"f .--'!r""1. I I l t/; t' , r: I _ Absolute CD4 _._%
Done l'-i Not done i l i,ll-:rill]iilUil;J _ Absolute CD4 _._%8. CD4 count collectedbefore this admission
i , ,' :r r L- ' 
-L---ii----
Note: Enter dote ol most recent
result ovailable
HIV RNA copies/ml
Viral load log
Note: Enter most recent result dvailable
9. HIV viral load Done :: trtot done i--l
10. Was a CXR done on the patient? Ves il No [f
Note lf not done go to Q 77
10.1. lf X-ray done record X- ray 
-number here:
Note: For KlerksdorpTshepong Hospital Complex only
10.2 Copy of X-ray downloaded? Yes fl No il
10.3 if yes, date X-ray copy download.d nnlIilliltt]il
L1. Bacterial Culture, done within 48 hours of admission?
Note: lf yes, complete the toble below, il no skip to Qll
r*::
i---lNoi^-':Yes
Date of culture
Site
Organism lsolated lf other (99), specify
Blood CSF Pleural fluid
l-- : []: i..l iliil :i i--l i:
lll-lrl-Il lrl Iilf llll
I llii ]l-:/l-r r: i.ti::j
i-t{-lrr:llrl-1 Tl L l []
Page 1 of 282
11.1 Blood Specimen and Culture taken by nso n ctini"iun
11.2. Blood Culture Specimen requested by clinician [ves n No
12. TB testing done during this admission? Yes ,:*-tL_i No il
Date of Test l-1 I -l ri*--l f--l rf--l 11 f-l l---1L' LJ' L-f 1._-._tr L-.-....' L._....-l t..._....; t.-..J I ll lll ll llr il il li IL-JUi l.---l L..-...1 I :.-.---l t..--...1 1,...-..i LJ tf t_"lrl_It:rlf niln ililrnilrilniln
Specimen*
AFB's present
(Yes/No/Not
Aoolicable)
r--T_- --r---.,-'ll , _j___L I [:L-m-".-] [:lil-l--- l mml
Culture Done
(Yes/No )
|-;-r,:-til'1'i fT.l ----r-:-"'1I LJ ;:r:l
Culture Results
(Positive/Negative/
Contaminated)
fr;,: Tr:,.T;,i'I
Date of final results report
l*} I- 1rl,I i_lril] i-: Ll n
Date of final results reportIl lrt ,i-"i,i'--ll"jl- ii:,:
f:r:1 l;,: f#f*l
Date offinal results report
ul-lrt-lt_lrif nilil Date of final results reporti. "l i-irll l--lrl: i- l i 
-i i]
GeneXpert Done f;*T''-l r,T
GeneXpert Results
(Positive/ Negative/
lnconclusive)
Tr;x-l r.n.; l_:l.;i,:*l | ,il-l-r'':r -l ,irr 
*l
*Specimen codes:
1=Sputum 2=GastricWashing 3=BoneMarrow 4=Pleural Aspirate 5=LymphNode 6=Other(ifother,write
in full)
Note: Culture results will be reviewed ot o loter date.
Do not deloy submission ol clF ond Result Form while waiting forTB culture results.
Note: complete the toble below for TSAP (For Edendole Hospitol KzN Only):
13. Was a blood count done during this admission?
Note: lf not done end; il yes, complete toble below
Yes il No u
Iltr.f] (looo/ur)
;][.n (106/pr)
IE.[]worr
nE.Etzr
EEX,E trt
fI[.n t*t
nE.Eltiart
ptatetets nnI.n (looo/ul) ! ruot recorded
Neutrophils Itr n (%wBc) [ rrrot recorded
Monocytes [I n (%wBc) [ rrrot recorded
lympocytes trtr.I (%wBc) I r,rot recorded
Eosinophils f,n.n (zowBc) f ruot recorded
Basophils In.I (%wBc) [ rtrot recorded
QC perfomed by: lnitials trntr Date:IE/trtrfltrIn
01 = No growth
;;; 
=, 
;; ; ;;; ; ;, 
" 
; ;-;  ;; ,: )
MRSA
Organism codes:
i 02= streptococcus pneumonioe i 03 = Haemophilus influenzae O4 = Klebsiella pneumonioe
06 
= 
Neiserria meningitides
07 = Coogulose negotive
staphylococcus /
Sto p hylo coccus e p ide rmid is
08 - Bocillus Species
09 = Corynebacterium species ll = Cryptococcus neoformons i tZ = Escherichio coli 13 = Solmonello species
15 = Acinetobocter boumanii i L6 = Pseudomonos oeruginosa L7 = Enterococcus foecalis14 = Streptococcus ogaloctiae /Group B Sfieptococcus
18 = Streptococcus viridons 79 = Micrococcus species
20 = Solmonella enterico_
Non-Typhodiol INTSI
27 = Solmonelld enterico- Typhi
22 = Salmonello porothyphi 99 = Other
SARI Surveillance Programme
Hospital Results Form (HRFI
\/a.ci^h.1R naramhar 7n1? Finel
PaEe 2 oI 2
I ir-,:, I ru;i l :-l:,:; I | ,-',,.,t, | :,,,''1: I i.:-'r: i I
WBC
MCH
MCHC
Hb
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Severe Acute Respiratorv lllness (SARI) Surveillance
Final Outcome Form (FOF)
Centre for Respiratory Diseases and Meningitis (CRDM)
TEt:011 386 5410 or 011 386 6434
FAX:086 723 3569
sARl Surveillance Programme
Final Outcome Form (FOF)
solnitials:i il il I SARI Study lD: Date of admission, l-j i^lll-l t]lil l*: iI il(DD/MM/YYYY)
Did any of the following occur during admission?
1.
2.
Was TB therapy started? Yes LJ ruo ll
ruo 1""".1Did the patient receive oxygen? Yes il
Did the patient receive mechanical ventilation?
Did the patient have a cardiac arrest?
was the patient admitteo,;;;---- 
-----
L] L]
4.
r'""1IIL,t L_,1
t: il
Did the patient go into shock
(Systolic BP < 90mmHg) or require inotropes?
IJ il
7. Antibiotics prescribed during this admission: ves [.--j
Note: I yes, complete the toble below. ff no/unknown, skip to Q I
No LJ Unk i:
PO tvt tMt Date started
(enter date prescribed)
Total number of
davs
Amoxicillin ilIfflnrilIlilil
Augmentin ili_liil[Irflililt:
Ceftriaxone (Rocephin) ilUrillfrilniln
Ciprofloxacin (Ciprobay) ilIifflffirl*-lilni::
Contrimoxazole (Bactrim) Uil;illtllrl-]ililm
Erythromycin i*ltf;ilffil-1nilff
Penicillin G Ilmnnrlli:1il.
Ampiclox IIUfliliilililn
Ampicillin ilnrillL:/ililili:
Cefotaxime Ll[]rili-11l-]:lilil
Cefuroxime (Zinnat) ilt[/L]ru/ilnilil
Clindamycin l*]iliilf]/Unilm
Doxycycline uiliuu,'ilnilm
Page I of 2
6. Yes No
84
-Gentamycin IlfrUilrlf nilt]
Vancomycin ilt-.iltXfrililllu
Metronidazole if [iI]tfflfIil
Other ( Specify): IlUrUl:ril{:iln
8. Was oseltamivir (Tamifluo) prescribed during this admission? Yes fl t'lo f] Unk f]
8.1 tf yes, date prescribed, i-jl];.-li*lii*j-:Ii..:
9. Was Pneumocystis jirovecii pneumonia (PCP) treatment prescribed during this admission? Yes l-] No lI Unk I
Note: ff yes, complete table below, if no or unknown skip to Final outcome oI Pdtient
Dose (Specify
quantity and
unit)
Oral tMt tvt Frequency Date started(enter date prescribed)
Total number of
days
Cotrimoxazole uilrtilrililnn
Dapsone LlUrlIlllrililUt:
Prednisone ul-lrulfrilililil:
Hydrocortisone ; 
.": "i , 
- 
:-::--1," ''lJ'-
i ll.,.il :,---.1'L..-ii..: J'
Other (specify) ililri]i]rnilrui:
Final outcomes of patient (for this admission)
10.1 What was the final outcome (for this admission)?
Discharge l-l Death i:
Referred to step down i:- Name of facility:
Transferred i : Name of facility:
10.2 Date offinal 
-""1,'_ . I 
-.: 
-- : -,. -
outcome:
Refused hospitaltreatment/absconded tl
1.1. Discha rgelfin
al diagnosis or
diagnosis on
tra nsfer/referral
Neonatal Sepsis f-] Bronchiolitis f]
SuspectedTB I ConfirmedTB I
Meningitis I Sepsis (not neonatal)
Bronchopneumonia/Pneu monia/Lower Respiratory Tract lnfection i-J
Bronchitis ll Diarrhoea [*-j Febrile seizures i' .i
I*: Not recorded fl other illl (specify)
Outcome follow up (for oll SAR| and SRI cases enrolled ot Edendale, Klerksdorp ond Tshepong Hospitols only)
12. Date of follow up: i*lijli]illfln;il Not done ll-l
12.1 what was the fottow up outcome? ,":1 I tf died, date of death ili-"ll[,]1-]il[li:lt-: Date Unk ll
Alive i-l Unknown (not possible to determine) | i
QC performed by: rnitiars: [**j |-j [: oate, i*l[]t' lII-jI_ji*ll_i
SARI Surveillance Programme
Final Outcome Form (FOFI
Verslonr 25-June-2O12
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